It	O
could	O
reduce	O
PI	O
significantly	O
more	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
placebo	O
controls	O
only	O
for	O
the	O
subgroup	O
with	O
mild	O
to	O
moderate	O
pain	O
,	O
but	O
not	O
with	O
severe	O
pain	O

For	O
pain	O
relief	O
,	O
ENS	O
was	O
significantly	O
better	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
EMS	O
;	O
but	O
for	O
the	O
improvement	O
of	O
ROM	O
,	O
EMS	O
was	O
significantly	O
better	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
than	O
ENS	O

It	O
is	O
concluded	O
that	O
ENS	T
is	O
more	O
effective	O
for	O
immediate	O
relief	O
of	O
myofascial	D
trigger	D
point	D
pain	D
than	O
EMS	T
,	O
and	O
EMS	T
has	O
a	O
better	O
effect	O
on	O
immediate	O
release	O
of	O
muscle	D
tightness	D
than	O
ENS	T

Because	O
activity	O
and	O
regular	O
exercise	O
are	O
important	O
factors	O
to	O
maintain	O
general	O
good	O
health	O
in	O
senior	O
citizens	O
,	O
we	O
investigated	O
whether	O
senior	O
dancing	O
has	O
any	O
effect	O
on	O
peripheral	O
or	O
lumbar	O
bone	O
density	O

We	O
performed	O
a	O
prospective	O
study	O
over	O
a12-mo	O
period	O
on	O
bone	O
density	O
at	O
a	O
spinal	O
and	O
peripheral	O
measuring	O
site	O
in	O
28	O
female	O
senior	O
members	O
(	O
mean	O
age	O
:	O
67	O
+/-	O
2	O
yr	O
)	O
of	O
a	O
dancing	O
group	O
in	O
Vienna	O

Lumbar	O
bone	O
mineral	O
density	O
was	O
assessed	O
by	O
quantitative	O
computed	O
tomography	O
(	O
qCT	O
)	O
and	O
radial	O
bone	O
density	O
by	O
single	O
photon	O
absorptiometry	O
of	O
the	O
distal	O
forearm	O

The	O
mean	O
training	O
time	O
per	O
week	O
was	O
3.2	O
+/-	O
0.8	O
h.	O
In	O
the	O
entire	O
group	O
of	O
female	O
dancers	O
,	O
no	O
significant	O
effects	O
of	O
dancing	O
on	O
radial	O
or	O
lumbar	O
bone	O
density	O
could	O
be	O
observed	O

Linear	O
regression	O
analysis	O
showed	O
that	O
the	O
lower	O
the	O
qCT	O
at	O
the	O
beginning	O
of	O
the	O
observation	O
period	O
,	O
the	O
higher	O
was	O
the	O
percentage	O
increase	O
of	O
spinal	O
qCT	O
in	O
the	O
entire	O
group	O
during	O
12	O
mo	O
of	O
dancing	O
(	O
r	O
=	O
0.52	O
,	O
P	O
&	O
#	O
60	O
;	O
0.0001	O
)	O

For	O
additional	O
evaluation	O
,	O
females	O
were	O
divided	O
into	O
two	O
subgroups	O
,	O
osteoporotic	O
or	O
nonosteoporotic	O
,	O
based	O
on	O
x-rays	O
and	O
lumbar	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
as	O
measured	O
by	O
qCT	O

The	O
group	O
classified	O
as	O
dancers	O
with	O
osteoporosis	O
(	O
group	O
I	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
lumbar	O
bone	O
density	O
,	O
whereas	O
in	O
the	O
group	O
of	O
dancers	O
without	O
signs	O
of	O
osteoporosis	D
(	O
group	O
II	O
)	O
,	O
BMD	O
remained	O
unchanged	O

Additionally	O
,	O
radial	O
bone	O
density	O
did	O
not	O
show	O
any	O
changes	O
in	O
either	O
group	O

Group	O
I	O
showed	O
a	O
significant	O
correlation	O
between	O
basal	O
spinal	O
BMD	O
and	O
the	O
percentage	O
change	O
of	O
BMD	O
during	O
the	O
observation	O
period	O
(	O
r	O
=	O
0.7	O
,	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O

Changes	O
of	O
the	O
biochemical	O
parameters	O
were	O
observed	O
in	O
the	O
bone-specific	O
isoenzyme	O
of	O
alkaline	O
phosphatase	O
,	O
a	O
marker	O
of	O
osteoblastic	O
activity	O
,	O
in	O
group	O
I	O
giving	O
additional	O
evidence	O
of	O
increased	O
bone	O
formation	O

OBJECTIVES	O
:	O
To	O
estimate	O
the	O
prevalence	O
of	O
Chlamydia	D
trachomatis	D
in	O
asymptomatic	O
women	O
attending	O
general	O
practice	O
:	O
to	O
assess	O
the	O
potential	O
of	O
the	O
ligase	O
chain	O
reaction	O
as	O
a	O
screening	O
tool	O
;	O
and	O
to	O
evaluate	O
selective	O
screening	O
criteria	O

DESIGN	O
:	O
Cross	O
sectional	O
survey	O

SETTING	O
:	O
Four	O
general	O
practices	O
in	O
northeast	O
London	O

SUBJECTS	O
:	O
890	O
women	O
aged	O
18-35	O
years	O
attending	O
general	O
practice	O
for	O
a	O
cervical	O
smear	O
or	O
a	O
``	O
young	O
well	O
woman	O
''	O
check	O
between	O
October	O
1994	O
and	O
January	O
1996	O

The	O
women	O
were	O
tested	O
for	O
C	D
trachomatis	D
with	O
confirmed	O
enzyme	O
immunoassay	O
(	O
endocervical	O
specimens	O
)	O
and	O
ligase	O
chain	O
reaction	O
assay	O
on	O
urine	O
specimens	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Prevalence	O
of	O
C	D
trachomatis	D
infection	D
in	O
women	O
aged	O
18-35	O
on	O
the	O
basis	O
of	O
each	O
test	O
;	O
sensitivity	O
and	O
specificity	O
of	O
both	O
tests	O
in	O
this	O
population	O

RESULTS	O
:	O
Prevalence	O
of	O
confirmed	O
infection	O
was	O
2.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
1.6	O
%	O
to	O
3.6	O
%	O
)	O
in	O
all	O
women	O

Prevalence	O
on	O
the	O
basis	O
of	O
enzyme	O
immunoassay	O
was	O
1.6	O
%	O
(	O
0.8	O
%	O
to	O
2.7	O
%	O
)	O
,	O
with	O
a	O
sensitivity	O
of	O
60	O
%	O
and	O
a	O
specificity	O
of	O
100	O
%	O

Prevalence	O
on	O
the	O
basis	O
of	O
ligase	O
chain	O
reaction	O
was	O
2.5	O
%	O
(	O
1.5	O
%	O
to	O
3.9	O
%	O
)	O
,	O
with	O
90	O
%	O
sensitivity	O
and	O
99.8	O
%	O
specificity	O

Screening	O
all	O
women	O
aged	O
&	O
#	O
60	O
;	O
or	O
=	O
25	O
and	O
all	O
women	O
who	O
had	O
had	O
two	O
or	O
more	O
partners	O
in	O
the	O
past	O
year	O
would	O
have	O
detected	O
87	O
%	O
(	O
20/23	O
)	O
of	O
infections	O

CONCLUSION	O
:	O
Ligase	O
chain	O
reaction	O
on	O
urine	O
samples	O
performs	O
at	O
least	O
as	O
well	O
as	O
enzyme	O
immunoassay	O
on	O
cervical	O
specimens	O
in	O
this	O
low	O
prevalence	O
population	O

It	O
offers	O
potential	O
as	O
a	O
non-invasive	O
screening	O
tool	O

A	O
simple	O
selective	O
screening	O
strategy	O
might	O
be	O
appropriate	O
and	O
would	O
be	O
able	O
to	O
detect	O
most	O
cases	O
of	O
infection	D

However	O
,	O
a	O
rigorous	O
economic	O
evaluation	O
of	O
possible	O
screening	O
strategies	O
is	O
needed	O
first	O

Recently	O
,	O
many	O
advances	O
have	O
been	O
made	O
in	O
the	O
study	O
of	O
sexual	O
differentiation	O
,	O
including	O
the	O
discoveries	O
of	O
the	O
gene	O
for	O
antimÃ1/4llerian	O
hormone	O
as	O
well	O
as	O
the	O
gene	O
for	O
its	O
receptor	O

However	O
,	O
the	O
etiology	O
of	O
the	O
clinical	O
syndrome	O
of	O
mÃ1/4llerian	O
agenesis	O
remains	O
elusive	O

We	O
hypothesize	O
that	O
activating	O
mutations	O
of	O
either	O
the	O
antimÃ1/4llerian	O
hormone	O
gene	O
or	O
its	O
receptor	O
gene	O
may	O
cause	O
mÃ1/4llerian	O
duct	O
regression	O
in	O
a	O
genetic	O
female	O
during	O
embryogenesis	O

This	O
clinical	O
commentary	O
discusses	O
the	O
current	O
management	O
of	O
the	O
syndrome	O
including	O
the	O
Abbe-McIndoe	T
procedure	T
,	O
the	O
most	O
commonly	O
used	O
method	O
of	O
surgical	T
correction	T
,	O
and	O
the	O
Frank	T
vaginal	T
dilation	T
method	T
,	O
the	O
most	O
common	O
nonsurgical	O
method	O
of	O
correction	O

OBJECTIVES	O
:	O
Obesity	D
is	O
an	O
important	O
clinical	O
problem	O
,	O
and	O
the	O
use	O
of	O
dexfenfluramine	T
hydrochloride	T
for	O
weight	O
reduction	O
has	O
been	O
widely	O
publicized	O
since	O
its	O
approval	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O

However	O
,	O
animal	O
and	O
human	O
studies	O
have	O
demonstrated	O
toxic	O
effects	O
of	O
fenfluramines	T
that	O
clinicians	O
should	O
be	O
aware	O
of	O
when	O
considering	O
prescribing	O
the	O
drugs	O

Our	O
purpose	O
was	O
to	O
systematically	O
review	O
data	O
on	O
brain	O
serotonin	O
neurotoxicity	O
in	O
animals	O
treated	O
with	O
fenfluramines	T
and	O
the	O
evidence	O
linking	O
fenfluramines	T
to	O
primary	D
pulmonary	D
hypertension	D
(	D
PPH	D
)	D

DATA	O
SOURCES	O
:	O
Archival	O
articles	O
and	O
reviews	O
identified	O
through	O
a	O
computerized	O
search	O
of	O
MEDLINE	O
from	O
1966	O
to	O
April	O
1997	O
using	O
``	O
fenfluramine	O
(	O
s	O
)	O
,	O
''	O
``	O
serotonin	O
,	O
''	O
``	O
neurotoxicity	O
,	O
''	O
``	O
behavior	O
,	O
''	O
``	O
anorexigens	O
,	O
''	O
``	O
weight	O
loss	O
,	O
''	O
and	O
``	O
primary	O
pulmonary	O
hypertension	O
''	O
as	O
index	O
terms	O

STUDY	O
SELECTION	O
:	O
Reports	O
dealing	O
with	O
long-term	O
effects	O
of	O
fenfluramines	T
on	O
brain	O
serotonin	O
neurons	O
,	O
body	O
weight	O
,	O
and	O
pulmonary	O
function	O
in	O
animals	O
and	O
humans	O

DATA	O
EXTRACTION	O
:	O
Reports	O
were	O
reviewed	O
by	O
individuals	O
with	O
expertise	O
in	O
serotonin	O
neurobiology	O
,	O
neurotoxicity	O
,	O
neuropsychiatry	O
,	O
and	O
pulmonary	O
medicine	O
and	O
evaluated	O
for	O
appropriateness	O
for	O
inclusion	O
in	O
this	O
review	O

DATA	O
SYNTHESIS	O
:	O
Fenfluramines	T
cause	O
dose-related	O
,	O
long-lasting	O
reductions	O
in	O
serotonin	O
axonal	O
markers	O
in	O
all	O
the	O
animal	O
species	O
tested	O
and	O
with	O
all	O
the	O
routes	O
of	O
drug	O
administration	O
used	O

Doses	O
of	O
fenfluramines	O
that	O
produce	O
signs	O
of	O
brain	O
serotonin	O
neurotoxicity	O
in	O
animals	O
are	O
on	O
the	O
same	O
order	O
as	O
those	O
used	O
to	O
treat	O
humans	O
for	O
weight	O
loss	O
when	O
one	O
takes	O
into	O
account	O
known	O
relations	O
between	O
body	O
mass	O
and	O
drug	O
clearance	O

However	O
,	O
no	O
human	O
studies	O
have	O
been	O
conducted	O
,	O
and	O
the	O
pathological	O
and	O
clinical	O
potential	O
for	O
neurotoxicity	O
in	O
humans	O
is	O
unknown	O

Appetite	O
suppressants-most	O
commonly	O
fenfluramines	T
-increase	O
the	O
risk	O
of	O
developing	O
PPH	D
(	O
odds	O
ratio	O
,	O
6.3	O
)	O
,	O
particularly	O
when	O
used	O
for	O
more	O
than	O
3	O
months	O
(	O
odds	O
ratio	O
,	O
>	O
20	O
)	O

CONCLUSIONS	O
:	O
Fenfluramine	T
and	O
dexfenfluramine	T
have	O
been	O
demonstrated	O
to	O
damage	O
brain	O
serotonin	O
neurons	O
in	O
animal	O
studies	O

It	O
is	O
not	O
known	O
if	O
such	O
damage	O
occurs	O
in	O
humans	O
or	O
if	O
there	O
are	O
clinical	O
consequences	O

Use	O
of	O
fenfluramines	T
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
PPH	D

Future	O
studies	O
should	O
address	O
the	O
long-term	O
consequences	O
of	O
prolonged	O
use	O
of	O
fenfluramines	T

Moxonidine	T
(	T
Physiotens-Solvay	T
)	T
was	O
introduced	O
last	O
year	O
as	O
the	O
first	O
of	O
a	O
new	O
class	O
of	O
centrally-acting	O
antihypertensive	T
agents	T
,	O
the	O
selective	O
imidazoline	O
receptor	O
agonists	O

The	O
manufacturer	O
claims	O
that	O
moxonidine	T
``	O
accurately	O
targets	O
imidazoline	O
receptors	O
at	O
the	O
cardiovascular	O
control	O
centre	O
in	O
the	O
brainstem	O
''	O
and	O
is	O
``	O
as	O
effective	O
as	O
current	O
first-line	O
therapies	O
for	O
essential	D
hypertension	D
``	O

Other	O
claims	O
suggest	O
that	O
it	O
causes	O
fewer	O
unwanted	O
effects	O
than	O
older	O
centrally-acting	O
antihypertensive	T
drugs	T
such	O
as	O
clonidine	T
and	O
methyldopa	T

Is	O
moxonidine	T
a	O
useful	O
addition	O
to	O
the	O
growing	O
number	O
of	O
antihypertensives	O
on	O
the	O
market	O
?	O

This	O
article	O
discusses	O
dental	O
anxiety	O
and	O
phobia	O

The	O
author	O
presents	O
background	O
information	O
,	O
including	O
incidence	O
and	O
etiology	O

A	O
discussion	O
of	O
evaluative	O
techniques	O
for	O
assessing	O
anxiety	O
levels	O
follows	O

Examination	O
and	O
treatment	O
planning	O
are	O
considered	O
in	O
relation	O
to	O
this	O
patient	O
's	O
special	O
needs	O

The	O
article	O
stresses	O
behavioral	O
treatment	O
modalities	O
that	O
eliminate	O
the	O
debilitating	O
phobia	O

In	O
closing	O
,	O
the	O
author	O
presents	O
practical	O
information	O
regarding	O
prevention	O
of	O
dental	O
phobia	O
and	O
the	O
merits	O
of	O
incorporating	O
this	O
type	O
of	O
patient	O
into	O
a	O
dental	O
practice	O

In	O
order	O
to	O
evaluate	O
the	O
applicability	O
of	O
anthelminthic	T
treatment	T
of	O
wild	O
foxes	O
(	O
Vulpes	O
vulpes	O
)	O
to	O
limit	O
their	O
infection	D
with	D
Echinococcus	D
multilocularis	D
,	O
bait	O
pellets	O
,	O
each	O
containing	O
50	O
mg	O
praziquantel	T
,	O
were	O
repeatedly	O
distributed	O
in	O
an	O
area	O
of	O
566	O
km2	O
where	O
many	O
foxes	O
are	O
infected	O
,	O
in	O
southern	O
Germany	O

After	O
six	O
baiting	O
campaigns	O
(	O
15-20	O
baits/km2	O
)	O
over	O
a	O
period	O
of	O
14	O
months	O
,	O
the	O
prevalence	O
of	O
the	O
cestode	O
in	O
foxes	O
,	O
initially	O
32	O
%	O
,	O
had	O
fallen	O
to	O
4	O
%	O

The	O
effect	O
was	O
most	O
pronounced	O
in	O
the	O
central	O
part	O
of	O
the	O
treated	O
area	O
,	O
where	O
no	O
positive	O
fox	O
was	O
found	O
in	O
the	O
2	O
months	O
before	O
the	O
end	O
of	O
the	O
trial	O

The	O
study	O
was	O
controlled	O
for	O
other	O
factors	O
that	O
could	O
influence	O
the	O
parasite	O
's	O
prevalence	O
,	O
such	O
as	O
the	O
availability	O
of	O
intermediate	O
hosts	O

While	O
the	O
potential	O
of	O
this	O
baiting	O
method	O
to	O
remove	O
E	O

multilocularis	O
from	O
wild	O
hosts	O
has	O
been	O
demonstrated	O
,	O
the	O
question	O
of	O
its	O
long-term	O
efficacy	O
and	O
other	O
unresolved	O
problems	O
have	O
to	O
be	O
addressed	O
by	O
consecutive	O
studies	O
before	O
routine	O
application	O
can	O
be	O
recommended	O

In	O
patients	O
with	O
chronic	D
myeloid	D
leukemia	D
(	D
CML	D
)	D
,	O
the	O
neoplastic	O
(	O
BCR-ABL+	O
)	O
progenitor	O
cells	O
are	O
characterized	O
by	O
an	O
increased	O
proliferative	O
activity	O

Whether	O
these	O
cells	O
are	O
also	O
resistant	O
to	O
apoptosis	O
and	O
if	O
so	O
,	O
under	O
what	O
conditions	O
remains	O
controversial	O

We	O
now	O
show	O
that	O
highly	O
purified	O
populations	O
of	O
very	O
primitive	O
neoplastic	O
progenitor	O
cells	O
obtained	O
directly	O
from	O
CML	O
patients	O
survive	O
and	O
proliferate	O
in	O
vitro	O
for	O
several	O
weeks	O
in	O
the	O
absence	O
of	O
any	O
added	O
growth	O
factors	O
(	O
except	O
insulin	O
)	O

In	O
contrast	O
,	O
purified	O
primary	O
normal	O
progenitors	O
maintained	O
under	O
the	O
same	O
conditions	O
die	O
rapidly	O

Nevertheless	O
,	O
both	O
primary	O
CML	O
cells	O
and	O
BCR-ABL+	O
BAF3	O
cells	O
show	O
the	O
same	O
dose-dependent	O
sensitivity	O
to	O
TNF-alpha	O
or	O
ceramide-induced	O
apoptosis	O
as	O
their	O
respective	O
normal	O
counterparts	O

In	O
fact	O
,	O
time	O
course	O
studies	O
demonstrated	O
an	O
even	O
faster	O
onset	O
of	O
apoptosis	O
in	O
ceramide-treated	O
BCR-ABL+	O
BAF3	O
cells	O
as	O
compared	O
to	O
normal	O
controls	O

BCR-ABL+	O
cells	O
treated	O
with	O
ceramide	O
also	O
showed	O
a	O
rapid	O
and	O
sequential	O
increase	O
in	O
the	O
tyrosine	O
phosphorylation	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
p46-56SHC	O
and	O
p120Cbl	O

These	O
findings	O
suggest	O
growth	O
factor	O
deprivation	O
and	O
treatment	O
with	O
TNF-alpha	O
or	O
ceramide	O
trigger	O
different	O
initial	O
events	O
both	O
of	O
which	O
can	O
lead	O
to	O
apoptosis	O
in	O
factor-dependent	O
hematopoietic	O
cells	O

However	O
,	O
in	O
the	O
first	O
case	O
,	O
activation	O
of	O
apoptosis	O
is	O
blocked	O
by	O
the	O
basal	O
activity	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
,	O
whereas	O
in	O
the	O
second	O
,	O
the	O
presence	O
of	O
p210	O
(	O
BCR-ABL	O
)	O
appears	O
to	O
accelerate	O
the	O
onset	O
of	O
apoptosis	O
by	O
a	O
mechanism	O
that	O
may	O
involve	O
an	O
activation	O
of	O
its	O
kinase	O
function	O

Clinically	O
,	O
the	O
hallmark	O
of	O
the	O
human	D
amnesic	D
syndrome	D
is	O
an	O
impaired	O
ability	O
to	O
consciously	O
recollect	O
or	O
remember	O
daily	O
events	O

If	O
the	O
medial	O
region	O
of	O
the	O
temporal	O
lobes	O
,	O
including	O
the	O
hippocampus	O
and	O
related	O
structures	O
,	O
is	O
critical	O
for	O
establishing	O
these	O
new	O
memories	O
,	O
then	O
this	O
brain	O
region	O
should	O
be	O
active	O
whenever	O
events	O
are	O
experienced	O
,	O
regardless	O
of	O
whether	O
subjects	O
are	O
asked	O
explicitly	O
to	O
learn	O
and	O
remember	O

Here	O
we	O
show	O
that	O
the	O
medial	O
temporal	O
region	O
is	O
active	O
during	O
encoding	O
and	O
that	O
the	O
hemisphere	O
activated	O
and	O
the	O
amount	O
of	O
activation	O
depend	O
on	O
the	O
type	O
of	O
stimulus	O
presented	O
(	O
objects	O
or	O
words	O
)	O
,	O
whether	O
the	O
stimulus	O
can	O
be	O
encoded	O
for	O
meaning	O
(	O
real	O
objects	O
and	O
words	O
versus	O
nonsense	O
objects	O
and	O
words	O
)	O
,	O
and	O
task	O
experience	O
(	O
first	O
versus	O
the	O
second	O
time	O
a	O
task	O
is	O
performed	O
)	O

These	O
findings	O
demonstrate	O
that	O
the	O
medial	O
temporal	O
lobe	O
memory	O
system	O
is	O
engaged	O
automatically	O
when	O
we	O
attend	O
to	O
a	O
perceptual	O
event	O
and	O
that	O
the	O
location	O
and	O
amount	O
of	O
activation	O
depend	O
on	O
stimulus	O
characteristics	O
(	O
physical	O
form	O
,	O
meaning	O
)	O
and	O
experience	O

The	O
involvement	O
of	O
structures	O
in	O
the	O
medial	O
temporal	O
lobe	O
during	O
the	O
encoding	O
of	O
visual	O
associations	O
was	O
studied	O
with	O
functional	O
magnetic	O
resonance	O
imaging	O

In	O
11	O
out	O
of	O
12	O
normal	O
healthy	O
volunteers	O
this	O
task	O
resulted	O
in	O
activation	O
in	O
posterior	O
portions	O
of	O
the	O
parahippocampal	O
region	O
,	O
close	O
to	O
the	O
collateral	O
sulcus	O

In	O
seven	O
subjects	O
activation	O
was	O
encountered	O
in	O
the	O
hippocampal	O
formation	O

The	O
visual	O
association	O
task	O
as	O
adapted	O
for	O
this	O
study	O
may	O
provide	O
a	O
sensitive	O
measure	O
to	O
study	O
anterograde	O
amnesia	O
prevalent	O
in	O
Alzheimer	O
's	O
disease	O

Therefore	O
,	O
the	O
present	O
paradigm	O
enables	O
the	O
study	O
of	O
individual	O
changes	O
in	O
learning	O
and	O
memory	O
capacities	O
over	O
time	O

Altered	O
calcium	O
(	O
Ca2+	O
)	O
homeostasis	O
is	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
aging	O
and	O
neuropathology	O
resulting	O
in	O
memory	O
deficits	O

Several	O
forms	O
of	O
hippocampal	O
synaptic	O
plasticity	O
are	O
dependent	O
on	O
Ca2+	O
,	O
providing	O
a	O
potential	O
link	O
between	O
altered	O
Ca2+	O
homeostasis	O
and	O
memory	O
deficits	O
associated	O
with	O
aging	O

The	O
current	O
study	O
reviews	O
evidence	O
for	O
Ca2+	O
dysregulation	O
during	O
aging	O
which	O
could	O
interact	O
with	O
Ca	O
(	O
2+	O
)	O
-dependent	O
synaptic	O
plasticity	O

The	O
authors	O
suggest	O
that	O
changes	O
in	O
Ca2+	O
regulation	O
could	O
adjust	O
the	O
thresholds	O
for	O
synaptic	O
modification	O
,	O
favoring	O
processes	O
for	O
depression	O
of	O
synaptic	O
strength	O
during	O
aging	O

Transiently	O
evolked	O
otoacoustic	O
emissions	O
(	O
TEOAE	O
)	O
have	O
been	O
reported	O
in	O
several	O
studies	O
as	O
absent	O
in	O
a	O
small	O
minority	O
of	O
normal	O
ears	O

Other	O
studies	O
have	O
reported	O
TEOAEs	O
in	O
all	O
normal	O
ears	O

Differences	O
between	O
studies	O
may	O
arise	O
directly	O
from	O
criteria	O
for	O
TEOAE	O
identification	O
,	O
criteria	O
for	O
selection	O
of	O
normals	O
,	O
or	O
statistically	O
due	O
to	O
limited	O
sample	O
sizes	O

In	O
order	O
to	O
understand	O
and	O
model	O
cochlear	O
processes	O
involved	O
in	O
TEOAE	O
generation	O
,	O
it	O
needs	O
to	O
be	O
known	O
whether	O
the	O
presence	O
of	O
normal	O
hearing	O
leads	O
automatically	O
to	O
generation	O
of	O
TEOAEs	O

The	O
present	O
study	O
set	O
out	O
to	O
establish	O
in	O
a	O
large	O
sample	O
if	O
any	O
ears	O
could	O
be	O
found	O
that	O
lacked	O
TEOAEs	O
despite	O
normal	O
hearing	O
threshold	O
levels	O
(	O
HTL	O
)	O

A	O
total	O
of	O
397	O
ears	O
from	O
highly	O
cooperative	O
adult	O
subjects	O
were	O
examined	O
under	O
laboratory	O
conditions	O

Using	O
cross	O
correlation	O
between	O
replicate	O
nonlinear	O
waveforms	O
as	O
the	O
criterion	O
,	O
TEOAEs	O
were	O
present	O
in	O
99.2	O
%	O
of	O
the	O
sample	O
(	O
lower	O
CI	O
98.1	O
%	O
)	O

However	O
,	O
careful	O
visual	O
assessment	O
of	O
the	O
recorded	O
waveforms	O
for	O
the	O
remaining	O
ears	O
did	O
not	O
unequivocally	O
show	O
absence	O
of	O
TEOAE	O
characteristics	O
in	O
any	O
ear	O
with	O
normal	O
HTLs	O

While	O
TEOAE	O
strength	O
varies	O
widely	O
among	O
ears	O
,	O
no	O
clear	O
evidence	O
was	O
found	O
to	O
show	O
that	O
TEOAEs	O
can	O
be	O
absent	O
when	O
HTLs	O
are	O
normal	O

In	O
addition	O
to	O
a	O
long	O
form	O
of	O
591	O
amino	O
acids	O
(	O
aa	O
)	O
,	O
two	O
other	O
forms	O
of	O
PRL	O
receptor	O
(	O
PRLR	O
)	O
,	O
differing	O
in	O
the	O
length	O
of	O
their	O
cytoplasmic	O
domains	O
,	O
have	O
been	O
identified	O
in	O
the	O
rat	O

The	O
Nb2	O
form	O
,	O
lacking	O
198	O
aa	O
in	O
the	O
cytoplasmic	O
domain	O
,	O
is	O
able	O
to	O
transmit	O
a	O
lactogenic	O
signal	O
similar	O
to	O
the	O
long	O
form	O
,	O
whereas	O
the	O
short	O
form	O
of	O
291	O
aa	O
is	O
inactive	O

The	O
ability	O
of	O
PRL	O
to	O
activate	O
the	O
promoter	O
of	O
the	O
beta-casein	O
gene	O
or	O
the	O
lactogenic	O
hormone	O
responsive	O
element	O
fused	O
to	O
the	O
luciferase	O
reporter	O
was	O
assessed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
or	O
293	O
fibroblasts	O
transiently	O
transfected	O
with	O
PRLR	O
cDNAs	O

The	O
function	O
of	O
the	O
short	O
form	O
was	O
examined	O
after	O
cotransfection	O
of	O
both	O
the	O
long	O
and	O
short	O
forms	O

These	O
results	O
clearly	O
show	O
that	O
the	O
short	O
form	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
through	O
the	O
formation	O
of	O
inactive	O
heterodimers	O
,	O
resulting	O
in	O
an	O
inhibition	O
of	O
Janus	O
kinase	O
2	O
(	O
JAK2	O
)	O
activation	O

The	O
present	O
study	O
also	O
investigates	O
the	O
possible	O
participation	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
signal	O
transduction	O
pathway	O
,	O
using	O
cotransfection	O
experiments	O
and	O
a	O
new	O
approach	O
that	O
selectively	O
determines	O
the	O
contribution	O
of	O
cytoplasmic	O
receptors	O
in	O
the	O
process	O
of	O
signal	O
transduction	O

We	O
cotransfected	O
Chinese	O
hamster	O
ovary	O
cells	O
with	O
two	O
cDNA	O
constructs	O
:	O
a	O
cytoplasmic	O
(	O
soluble	O
)	O
form	O
of	O
the	O
receptor	O
with	O
a	O
deleted	O
signal	O
peptide	O
(	O
delta-19	O
)	O
,	O
which	O
is	O
unable	O
to	O
bind	O
PRL	O
,	O
and	O
a	O
functionally	O
inactive	O
receptor	O
mutant	O
(	O
lacking	O
box	O
1	O
)	O
,	O
which	O
is	O
anchored	O
in	O
the	O
plasma	O
membrane	O
and	O
able	O
to	O
bind	O
PRL	O

This	O
approach	O
has	O
allowed	O
us	O
to	O
show	O
that	O
delta-19	O
,	O
lacking	O
expression	O
at	O
the	O
plasma	O
membrane	O
,	O
can	O
transduce	O
the	O
hormonal	O
message	O
,	O
at	O
least	O
to	O
a	O
limited	O
extent	O
(	O
up	O
to	O
30	O
%	O
of	O
wild	O
type	O
efficiency	O
)	O
,	O
providing	O
that	O
association/activation	O
occurs	O
with	O
a	O
PRL-PRLR	O
complex	O
initiated	O
at	O
the	O
cell	O
surface	O
level	O
;	O
box	O
1	O
of	O
the	O
cytoplasmic	O
form	O
is	O
necessary	O
to	O
rescue	O
this	O
partial	O
transcriptional	O
activity	O
of	O
the	O
inactive	O
mutant	O

This	O
partial	O
recovery	O
is	O
also	O
parallel	O
to	O
the	O
partial	O
activation	O
of	O
JAK2	O
,	O
indicating	O
that	O
the	O
signal	O
transduction	O
pathway	O
implicated	O
JAK2	O

Our	O
results	O
provide	O
evidence	O
that	O
heterodimerization	O
of	O
receptors	O
can	O
be	O
implicated	O
either	O
in	O
the	O
positive	O
or	O
in	O
negative	O
activation	O
of	O
gene	O
transcription	O

BACKGROUND	O
:	O
Inadequate	O
dietary	O
intake	O
of	O
calcium	O
and	O
vitamin	O
D	O
may	O
contribute	O
to	O
the	O
high	O
prevalence	O
of	O
osteoporosis	D
among	O
older	O
persons	O

METHODS	O
:	O
We	O
studied	O
the	O
effects	O
of	O
three	O
years	O
of	O
dietary	O
supplementation	O
with	O
calcium	O
and	O
vitamin	O
D	O
on	O
bone	O
mineral	O
density	O
,	O
biochemical	O
measures	O
of	O
bone	O
metabolism	O
,	O
and	O
the	O
incidence	O
of	O
nonvertebral	O
fractures	O
in	O
176	O
men	O
and	O
213	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
were	O
living	O
at	O
home	O

They	O
received	O
either	O
500	O
mg	O
of	O
calcium	O
plus	O
700	O
IU	O
of	O
vitamin	O
D3	O
(	O
cholecalciferol	O
)	O
per	O
day	O
or	O
placebo	O

Bone	O
mineral	O
density	O
was	O
measured	O
by	O
dual-energy	O
x-ray	O
absorptiometry	O
,	O
blood	O
and	O
urine	O
were	O
analyzed	O
every	O
six	O
months	O
,	O
and	O
cases	O
of	O
nonvertebral	O
fracture	O
were	O
ascertained	O
by	O
means	O
of	O
interviews	O
and	O
verified	O
with	O
use	O
of	O
hospital	O
records	O

RESULTS	O
:	O
The	O
mean	O
(	O
+/-SD	O
)	O
changes	O
in	O
bone	O
mineral	O
density	O
in	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
were	O
as	O
follows	O
:	O
femoral	O
neck	O
,	O
+0.50+/-4.80	O
and	O
-0.70+/-5.03	O
percent	O
,	O
respectively	O
(	O
P=0.02	O
)	O
;	O
spine	O
,	O
+2.12+/-4.06	O
and	O
+1.22+/-4.25	O
percent	O
(	O
P=0.04	O
)	O
;	O
and	O
total	O
body	O
,	O
+0.06+/-1.83	O
and	O
-1.09+/-1.71	O
percent	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O

The	O
difference	O
between	O
the	O
calcium-vitamin	O
D	O
and	O
placebo	O
groups	O
was	O
significant	O
at	O
all	O
skeletal	O
sites	O
after	O
one	O
year	O
,	O
but	O
it	O
was	O
significant	O
only	O
for	O
total-body	O
bone	O
mineral	O
density	O
in	O
the	O
second	O
and	O
third	O
years	O

Of	O
37	O
subjects	O
who	O
had	O
nonvertebral	O
fractures	O
,	O
26	O
were	O
in	O
the	O
placebo	O
group	O
and	O
11	O
were	O
in	O
the	O
calcium-vitamin	O
D	O
group	O
(	O
P=0.02	O
)	O

CONCLUSIONS	O
:	O
In	O
men	O
and	O
women	O
65	O
years	O
of	O
age	O
or	O
older	O
who	O
are	O
living	O
in	O
the	O
community	O
,	O
dietary	T
supplementation	T
with	T
calcium	T
and	T
vitamin	T
D	T
moderately	O
reduced	O
bone	D
loss	D
measured	O
in	O
the	O
femoral	O
neck	O
,	O
spine	O
,	O
and	O
total	O
body	O
over	O
the	O
three-year	O
study	O
period	O
and	O
reduced	O
the	O
incidence	O
of	O
nonvertebral	D
fractures	D

The	O
sterilization	O
and	O
contaminated	O
waste	O
disposal	O
practices	O
in	O
all	O
14	O
dental	O
clinics	O
operated	O
by	O
the	O
Southern	O
Sydney	O
Area	O
Health	O
Service	O
were	O
surveyed	O

All	O
of	O
the	O
clinics	O
used	O
autoclaves	O
for	O
sterilization	O

All	O
hand	O
instruments	O
,	O
handpieces	O
and	O
triplex	O
syringes	O
were	O
autoclaved	O
between	O
patients	O

Chemical	O
disinfection	O
solutions	O
were	O
used	O
in	O
12	O
of	O
the	O
14	O
dental	O
clinics	O
,	O
mainly	O
for	O
surface	O
decontamination	O

Five	O
dental	O
clinics	O
had	O
separate	O
storage	O
areas	O
for	O
contaminated	O
waste	O
which	O
compiled	O
with	O
contaminated	O
waste	O
separation	O
and	O
disposal	O
guidelines	O

The	O
practice	O
of	O
recapping	O
needles	O
with	O
fingers	O
and	O
some	O
inadequate	O
washing	O
facilities	O
are	O
areas	O
that	O
require	O
particular	O
attention	O

Safety	O
and	O
efficacy	O
are	O
crucial	O
but	O
separate	O
issues	O
for	O
vitamin	O
and	O
mineral	O
supplements	O

Misinterpretation	O
of	O
``	O
safe	O
and	O
adequate	O
''	O
to	O
mean	O
``	O
safety	O
limit	O
''	O
would	O
impose	O
restrictions	O
on	O
vitamin	O
and	O
mineral	O
intakes	O
that	O
are	O
not	O
needed	O
to	O
ensure	O
safety	O

Substantial	O
evidence	O
indicates	O
that	O
intakes	O
greater	O
than	O
the	O
recommended	O
dietary	O
allowances	O
(	O
RDAs	O
)	O
of	O
certain	O
vitamins	O
and	O
minerals	O
such	O
as	O
calcium	O
,	O
folic	O
acid	O
,	O
vitamin	O
E	O
,	O
selenium	O
,	O
and	O
chromium	O
reduce	O
the	O
risk	O
of	O
certain	O
diseases	O
for	O
some	O
people	O

Limitation	O
of	O
intakes	O
to	O
the	O
RDAs	O
would	O
preclude	O
reductions	O
in	O
disease	O
risk	O
from	O
these	O
nutrients	O

The	O
margin	O
of	O
safety	O
between	O
the	O
usual	O
dietary	O
intake	O
and	O
the	O
intake	O
that	O
would	O
produce	O
adverse	O
effects	O
varies	O
greatly	O
among	O
the	O
different	O
nutrients	O

Very	O
high	O
intakes	O
of	O
vitamins	O
A	O
and	O
D	O
,	O
niacin	O
,	O
pyridoxine	O
,	O
and	O
selenium	O
have	O
produced	O
adverse	O
effects	O

Many	O
widely	O
discussed	O
putative	O
adverse	O
effects	O
of	O
vitamin	O
C	O
,	O
vitamin	O
E	O
,	O
and	O
trivalent	O
chromium	O
have	O
little	O
factual	O
basis	O

There	O
is	O
no	O
evidence	O
of	O
adverse	O
effects	O
from	O
beta-carotene	O
supplements	O
except	O
in	O
current	O
heavy	O
smokers	O

The	O
mutator	O
hypothesis	O
of	O
tumorigenesis	O
suggests	O
that	O
loss	O
of	O
chromosomal	O
stability	O
or	O
maintenance	O
functions	O
results	O
in	O
elevated	O
mutation	O
rates	O
,	O
leading	O
to	O
the	O
accumulation	O
of	O
the	O
numerous	O
mutations	O
required	O
for	O
multistep	O
carcinogenesis	O

The	O
human	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
are	O
highly	O
conserved	O
homologues	O
of	O
the	O
Escherichia	O
coli	O
MutHLS	O
system	O
,	O
which	O
contribute	O
to	O
genomic	O
stability	O
by	O
surveillance	O
and	O
repair	O
of	O
replication	O
misincorporation	O
errors	O
and	O
exogenous	O
DNA	O
damage	O

Mutations	O
in	O
one	O
of	O
these	O
MMR	O
genes	O
,	O
hMSH2	O
,	O
account	O
for	O
about	O
half	O
of	O
all	O
cases	O
of	O
genetically	O
linked	O
hereditary	O
non-polyposis	O
colorectal	O
cancer	O

Loss	O
of	O
function	O
of	O
p53	O
has	O
also	O
been	O
proposed	O
to	O
increase	O
cellular	O
hypermutability	O
,	O
thereby	O
accelerating	O
carcinogenesis	O
,	O
although	O
a	O
clear	O
role	O
for	O
p53	O
in	O
genomic	O
instability	O
remains	O
controversial	O

p53	O
is	O
mutated	O
frequently	O
in	O
a	O
wide	O
range	O
of	O
human	O
cancers	D
,	O
including	O
colonic	D
tumours	D

Both	O
Msh2-	O
and	O
p53-targeted	O
knockout	O
mice	O
are	O
viable	O
and	O
susceptible	O
to	O
cancer	D

Here	O
we	O
demonstrate	O
that	O
combined	O
Msh2	O
and	O
p53	O
ablation	O
(	O
Msh2-/-p53-/-	O
)	O
results	O
in	O
developmental	O
arrest	O
of	O
all	O
female	O
embryos	O
at	O
9.5	O
days	O

In	O
contrast	O
,	O
male	O
Msh2-/-p53-/-	O
mice	O
are	O
viable	O
,	O
but	O
succumb	O
to	O
tumours	D
significantly	O
earlier	O
(	O
t1-2	O
is	O
73	O
days	O
)	O
than	O
either	O
Msh2-/-	O
or	O
p53-/-	O
littermates	O

Furthermore	O
,	O
the	O
frequency	O
of	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
in	O
tumours	O
from	O
Msh2-/-p53-/-	O
mice	O
is	O
not	O
significantly	O
different	O
than	O
in	O
Msh2-/-	O
mice	O

Synergism	O
in	O
tumorigenesis	O
and	O
independent	O
segregation	O
of	O
the	O
MSI	O
phenotype	O
suggest	O
that	O
Msh2	O
and	O
p53	O
are	O
not	O
genetically	O
epistatic	O

Our	O
data	O
(	O
Reddy	O
et	O
al	O
.	O
,	O
Radiat	O

Res	O

141	O
,	O
252-258	O
,	O
1995	O
)	O
on	O
the	O
kinetics	O
of	O
the	O
repair	O
of	O
potentially	O
lethal	O
damage	O
in	O
log-phase	O
Chinese	O
hamster	O
V79	O
cells	O
are	O
used	O
to	O
test	O
some	O
predictions	O
which	O
arise	O
from	O
the	O
different	O
assumptions	O
of	O
the	O
repair-misrepair	O
(	O
RMR	O
)	O
(	O
C	O

A	O

Tobias	O
,	O
Radiat	O

Res	O

104	O
,	O
S77-S95	O
,	O
1985	O
)	O
,	O
lethal-potentially	O
lethal	O
(	O
LPL	O
)	O
(	O
S.	O
B	O

Curtis	O
,	O
Radiat	O

Res	O

106	O
,	O
252-270	O
,	O
1986	O
)	O
and	O
double-strand	O
break	O
(	O
DSB	O
)	O
(	O
J	O

Y	O

Ostashevsky	O
,	O
Radiat	O

Res	O

118	O
,	O
437-466	O
,	O
1989	O
)	O
models	O

The	O
LPL	O
model	O
defines	O
the	O
time	O
available	O
for	O
repair	O
of	O
PLD	O
(	O
t	O
(	O
rep	O
)	O
)	O
as	O
the	O
time	O
taken	O
to	O
reach	O
maximal	O
survival	O
in	O
a	O
delayed-plating	O
recovery	O
experiment	O

Those	O
data	O
show	O
that	O
after	O
this	O
time	O
has	O
elapsed	O
,	O
contrary	O
to	O
the	O
expectation	O
of	O
the	O
LPL	O
model	O
,	O
survival	O
can	O
be	O
increased	O
by	O
changing	O
the	O
medium	O
used	O
for	O
delayed	O
plating	O
from	O
fresh	O
growth	O
medium	O
to	O
conditioned	O
medium	O

According	O
to	O
the	O
RMR	O
model	O
,	O
all	O
potentially	O
lethal	O
lesions	O
should	O
also	O
be	O
committed	O
by	O
that	O
time	O
and	O
be	O
unavailable	O
for	O
repair	O
in	O
the	O
new	O
medium	O

Only	O
the	O
DSB	O
model	O
correctly	O
predicted	O
that	O
PLD	O
(	O
=	O
DSBs	O
)	O
would	O
still	O
be	O
available	O
for	O
repair	O
after	O
that	O
time	O

Second	O
,	O
data	O
for	O
split-dose	O
recovery	O
are	O
used	O
to	O
predict	O
the	O
first-order	O
kinetics	O
time	O
constant	O
for	O
DSB	O
repair	O
(	O
tau	O
(	O
DSBR	O
)	O
)	O
using	O
the	O
DSB	O
model	O
(	O
24	O
+/-	O
1.5	O
min	O
)	O

This	O
value	O
is	O
nearly	O
identical	O
to	O
the	O
value	O
of	O
27	O
+/-	O
1	O
min	O
determined	O
from	O
the	O
data	O
obtained	O
by	O
Cheong	O
et	O
al	O
.	O
using	O
pulsed-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
(	O
Mutat	O

Res	O

274	O
,	O
111-122	O
,	O
1992	O
)	O

The	O
value	O
based	O
on	O
PFGE	O
is	O
used	O
to	O
calculate	O
the	O
value	O
of	O
t	O
(	O
rep	O
)	O
predicted	O
by	O
the	O
DSB	O
model	O
(	O
2.6	O
+/-	O
0.1	O
h	O
)	O
,	O
which	O
agrees	O
with	O
the	O
value	O
determined	O
experimentally	O
as	O
the	O
time	O
when	O
changing	O
the	O
delayed-plating	O
medium	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
with	O
delayed	O
plating	O
in	O
conditioned	O
medium	O
(	O
2.5	O
h	O
)	O

However	O
,	O
some	O
recovery	O
was	O
seen	O
for	O
a	O
change	O
in	O
the	O
medium	O
(	O
growth	O
medium	O
to	O
conditioned	O
medium	O
)	O
up	O
to	O
5-6	O
h	O
postirradiation	O

Reanalysis	O
of	O
the	O
original	O
data	O
on	O
DSB	O
repair	O
shows	O
that	O
they	O
are	O
consistent	O
with	O
two	O
first-order	O
repair	O
rates	O
(	O
18	O
+/-	O
7	O
min	O
and	O
about	O
52	O
min	O
)	O

These	O
results	O
are	O
consistent	O
with	O
two	O
pools	O
of	O
DSBs	O
(	O
or	O
cells	O
)	O
,	O
each	O
with	O
their	O
own	O
t	O
(	O
rep	O
)	O

The	O
early	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
fast	O
)	O
,	O
is	O
predicted	O
to	O
be	O
1.7	O
+/-	O
0.7	O
h	O
,	O
and	O
the	O
late	O
t	O
(	O
rep	O
)	O
,	O
associated	O
with	O
tau	O
(	O
slow	O
)	O
,	O
is	O
predicted	O
to	O
be	O
about	O
5	O
h.	O
Both	O
values	O
are	O
in	O
excellent	O
agreement	O
with	O
the	O
times	O
at	O
which	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
no	O
longer	O
gives	O
the	O
full	O
recovery	O
seen	O
in	O
conditioned	O
medium	O
only	O
(	O
the	O
early	O
t	O
(	O
rep	O
)	O
)	O
,	O
and	O
the	O
time	O
when	O
changing	O
from	O
growth	O
medium	O
to	O
conditioned	O
medium	O
produces	O
no	O
further	O
increase	O
in	O
survival	O
(	O
the	O
late	O
t	O
(	O
rep	O
)	O
)	O
,	O
respectively	O

It	O
is	O
noted	O
that	O
attempts	O
to	O
correlate	O
radiosensitivity	O
with	O
the	O
rates	O
of	O
DSB	O
repair	O
,	O
rather	O
than	O
using	O
an	O
explicit	O
model	O
such	O
as	O
the	O
DSB	O
model	O
,	O
are	O
unlikely	O
to	O
be	O
productive	O
since	O
survival	O
depends	O
on	O
both	O
tau	O
(	O
DSBR	O
)	O
and	O
t	O
(	O
rep	O
)	O
(	O
as	O
defined	O
in	O
the	O
DSB	O
model	O
)	O
and	O
the	O
latter	O
may	O
be	O
the	O
more	O
important	O
determinant	O
of	O
radiosensitivity	O
(	O
as	O
it	O
appears	O
to	O
be	O
for	O
ataxia	O
telangiectasia	O
cells	O
compared	O
to	O
normal	O
fibroblasts	O
and	O
for	O
irs	O
compared	O
to	O
V79	O
cells	O
)	O

CONTEXT	O
:	O
Adolescents	O
'	O
concerns	O
about	O
privacy	O
in	O
clinical	O
settings	O
decrease	O
their	O
willingness	O
to	O
seek	O
health	O
care	O
for	O
sensitive	O
problems	O
and	O
may	O
inhibit	O
their	O
communication	O
with	O
physicians	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
influence	O
of	O
physicians	O
'	O
assurances	O
of	O
confidentiality	O
on	O
adolescents	O
'	O
willingness	O
to	O
disclose	O
information	O
and	O
seek	O
future	O
health	O
care	O

DESIGN	O
:	O
Randomized	O
controlled	O
trial	O

SETTING	O
:	O
Three	O
suburban	O
public	O
high	O
schools	O
in	O
California	O

PARTICIPANTS	O
:	O
The	O
562	O
participating	O
adolescents	O
represented	O
92	O
%	O
of	O
students	O
in	O
mandatory	O
classes	O

INTERVENTION	O
:	O
After	O
random	O
assignment	O
to	O
1	O
of	O
3	O
groups	O
,	O
the	O
adolescents	O
listened	O
to	O
a	O
standardized	O
audiotape	O
depiction	O
of	O
an	O
office	O
visit	O
during	O
which	O
they	O
heard	O
a	O
physician	O
who	O
assured	O
unconditional	O
confidentiality	O
,	O
a	O
physician	O
who	O
assured	O
conditional	O
confidentiality	O
,	O
or	O
a	O
physician	O
who	O
did	O
not	O
mention	O
confidentiality	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Adolescents	O
'	O
willingness	O
to	O
disclose	O
general	O
information	O
,	O
willingness	O
to	O
disclose	O
information	O
about	O
sensitive	O
topics	O
,	O
intended	O
honesty	O
,	O
and	O
likelihood	O
of	O
return	O
visits	O
to	O
the	O
physician	O
depicted	O
in	O
the	O
scenario	O
were	O
assessed	O
by	O
anonymous	O
written	O
questionnaire	O

RESULTS	O
:	O
Assurances	O
of	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
disclose	O
sensitive	O
information	O
about	O
sexuality	O
,	O
substance	O
use	O
,	O
and	O
mental	O
health	O
from	O
39	O
%	O
(	O
68/175	O
)	O
to	O
46.5	O
%	O
(	O
178/383	O
)	O
(	O
beta=.10	O
,	O
P=.02	O
)	O
and	O
increased	O
the	O
number	O
willing	O
to	O
seek	O
future	O
health	O
care	O
from	O
53	O
%	O
(	O
93/175	O
)	O
to	O
67	O
%	O
(	O
259/386	O
)	O
(	O
beta=.17	O
,	O
P	O
&	O
#	O
60	O
;	O
.001	O
)	O

When	O
comparing	O
the	O
unconditional	O
with	O
the	O
conditional	O
groups	O
,	O
assurances	O
of	O
unconditional	O
confidentiality	O
increased	O
the	O
number	O
of	O
adolescents	O
willing	O
to	O
return	O
for	O
a	O
future	O
visit	O
by	O
10	O
percentage	O
points	O
,	O
from	O
62	O
%	O
(	O
122/196	O
)	O
to	O
72	O
%	O
(	O
137/190	O
)	O
(	O
beta=.14	O
,	O
P=.001	O
)	O

CONCLUSIONS	O
:	O
Adolescents	O
are	O
more	O
willing	O
to	O
communicate	O
with	O
and	O
seek	O
health	O
care	O
from	O
physicians	O
who	O
assure	O
confidentiality	O

Further	O
investigation	O
is	O
needed	O
to	O
identify	O
a	O
confidentiality	O
assurance	O
statement	O
that	O
explains	O
the	O
legal	O
and	O
ethical	O
limitations	O
of	O
confidentiality	O
without	O
decreasing	O
adolescents	O
'	O
likelihood	O
of	O
seeking	O
future	O
health	O
care	O
for	O
routine	O
and	O
nonreportable	O
sensitive	O
health	O
concerns	O

BACKGROUND	O
:	O
Diabetic	O
foot	D
infections	D
cause	O
substantial	O
morbidity	O
and	O
mortality	O

Neutrophil	O
superoxide	O
generation	O
,	O
a	O
crucial	O
part	O
of	O
neutrophil	O
bactericidal	O
activity	O
,	O
is	O
impaired	O
in	O
diabetes	D

Granulocyte-colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
increases	O
the	O
release	O
of	O
neutrophils	O
from	O
the	O
bone	O
marrow	O
and	O
improves	O
neutrophil	O
function	O

We	O
assessed	O
G-CSF	T
as	O
adjuvant	O
therapy	O
for	O
the	O
treatment	O
of	O
severe	D
foot	D
infections	D
in	D
diabetic	D
patients	D

METHODS	O
:	O
40	O
diabetic	O
patients	O
with	O
foot	D
infections	D
were	O
enrolled	O
in	O
a	O
double-blind	O
placebo-controlled	O
study	O

On	O
admission	O
,	O
patients	O
were	O
randomly	O
assigned	O
G-CSF	T
(	T
filgrastim	T
)	T
therapy	T
(	O
n	O
=	O
20	O
)	O
or	O
placebo	O
(	O
n	O
=	O
20	O
)	O
for	O
7	O
days	O

Both	O
groups	O
received	O
similar	O
antibiotic	T
and	T
insulin	T
treatment	T

Neutrophils	O
from	O
the	O
peripheral	O
blood	O
of	O
these	O
participants	O
and	O
from	O
healthy	O
controls	O
were	O
stimulated	O
with	O
opsonised	O
zymosan	O
,	O
and	O
superoxide	O
production	O
was	O
measured	O
by	O
a	O
spectrophotometric	O
assay	O
(	O
reduction	O
of	O
ferricytochrome	O
C	O
)	O

<	O
TO_SEE	O
>	O
FINDINGS	O
:	O
G-CSF	O
therapy	O
was	O
associated	O
with	O
earlier	O
eradication	O
of	O
pathogens	O
from	O
the	O
infected	O
ulcer	O
(	O
median	O
4	O
(	O
range	O
2-10	O
)	O
vs	O
8	O
(	O
2-79	O
)	O
days	O
in	O
the	O
placebo	O
group	O
;	O
p	O
=	O
0.02	O
)	O
,	O
quicker	O
resolution	O
of	O
cellulitis	O
<	O
(	O
7	O
(	O
5-20	O
)	O
vs	O
12	O
(	O
5-93	O
)	O
days	O
;	O
p	O
=	O
0.03	O
)	O
,	O
shorter	O
hospital	O
stay	O
(	O
10	O
(	O
7-31	O
)	O
vs	O
17.5	O
(	O
9-100	O
)	O
days	O
;	O
p	O
=	O
0.02	O
)	O
,	O
and	O
a	O
shorter	O
duration	O
of	O
intravenous	O
antibiotic	O
treatment	O
(	O
8.5	O
(	O
5-30	O
)	O
vs	O
14.5	O
(	O
8-63	O
)	O
days	O
;	O
p	O
=	O
0.02	O
)	O

No	O
G-CSF-treated	O
patient	O
needed	O
surgery	T
,	O
whereas	O
two	O
placebo	O
recipients	O
underwent	O
to	O
amputation	T
and	O
two	O
had	O
extensive	O
debridement	T
under	O
anaesthesia	O

After	O
7	O
days	O
'	O
treatment	O
,	O
neutrophil	O
superoxide	O
production	O
was	O
significantly	O
higher	O
in	O
the	O
G-CSF	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
16.1	O
(	O
4.2-24.2	O
)	O
vs	O
7.3	O
(	O
2.1-11.5	O
)	O
nmol	O
per	O
10	O
(	O
6	O
)	O
neutrophils	O
in	O
30	O
min	O
;	O
p	O
&	O
#	O
60	O
;	O
0.0001	O
)	O

G-CSF	T
therapy	T
was	O
generally	O
well	O
tolerated	O

INTERPRETATION	O
:	O
G-CSF	T
treatment	T
was	O
associated	O
with	O
improved	O
clinical	O
outcome	O
of	O
foot	D
infection	D
in	D
diabetic	D
patients	D

This	O
improvement	O
may	O
be	O
related	O
to	O
an	O
increase	O
in	O
neutrophil	O
superoxide	O
production	O

BACKGROUND	O
:	O
Accelerated	T
infusion	T
of	T
alteplase	T
(	T
tissue	T
plasminogen	T
activator	T
)	T
over	O
a	O
period	O
of	O
90	O
minutes	O
induces	O
more	O
rapid	O
lysis	O
of	O
coronary-artery	D
thrombi	D
than	O
a	O
3-hour	O
infusion	O

With	O
two	O
bolus	O
doses	O
of	O
alteplase	T
,	O
further	O
shortening	O
the	O
duration	O
of	O
administration	O
,	O
complete	O
reperfusion	O
was	O
achieved	O
in	O
more	O
than	O
85	O
percent	O
of	O
the	O
patients	O
in	O
initial	O
angiographic	O
studies	O

We	O
tested	O
the	O
hypothesis	O
that	O
double-bolus	T
alteplase	T
is	O
at	O
least	O
as	O
effective	O
as	O
accelerated	O
infusion	O

METHODS	O
:	O
In	O
398	O
hospitals	O
,	O
7169	O
patients	O
with	O
acute	D
myocardial	D
infarction	D
were	O
randomly	O
assigned	O
to	O
weight-adjusted	O
,	O
accelerated	O
infusion	O
of	O
100	O
mg	O
of	O
alteplase	T
or	O
to	O
a	O
bolus	O
of	O
50	O
mg	O
of	O
alteplase	T
over	O
a	O
period	O
of	O
1	O
to	O
3	O
minutes	O
followed	O
30	O
minutes	O
later	O
by	O
a	O
second	O
bolus	O
of	O
50	O
mg	O
(	O
or	O
40	O
mg	O
for	O
patients	O
who	O
weighed	O
less	O
than	O
60	O
kg	O
)	O

The	O
primary	O
end	O
point	O
was	O
death	O
from	O
any	O
cause	O
at	O
30	O
days	O

The	O
trial	O
was	O
stopped	O
prematurely	O
because	O
of	O
concern	O
about	O
the	O
safety	O
of	O
the	O
double-bolus	T
injection	T

RESULTS	O
:	O
Thirty-day	O
mortality	O
was	O
higher	O
in	O
the	O
double-bolus	O
group	O
than	O
in	O
the	O
accelerated-infusion	O
group	O
:	O
7.98	O
percent	O
as	O
compared	O
with	O
7.53	O
percent	O

The	O
absolute	O
difference	O
was	O
0.44	O
percent	O
,	O
with	O
a	O
one-sided	O
95	O
percent	O
upper	O
boundary	O
of	O
1.49	O
percent	O
,	O
which	O
exceeded	O
the	O
prespecified	O
upper	O
limit	O
of	O
0.40	O
percent	O
to	O
indicate	O
equivalence	O
in	O
30-day	O
mortality	O
between	O
the	O
two	O
regimens	O

The	O
respective	O
rates	O
of	O
any	O
stroke	D
and	O
of	O
hemorrhagic	D
stroke	D
were	O
1.92	O
and	O
1.12	O
percent	O
after	O
double-bolus	O
alteplase	T
,	O
as	O
compared	O
with	O
1.53	O
and	O
0.81	O
percent	O
after	O
an	O
accelerated	O
infusion	O
of	O
alteplase	T
(	O
P=0.24	O
and	O
P=0.23	O
,	O
respectively	O
)	O

CONCLUSIONS	O
:	O
Double-bolus	O
alteplase	T
was	O
not	O
shown	O
to	O
be	O
equivalent	O
,	O
according	O
to	O
the	O
prespecified	O
criteria	O
,	O
to	O
accelerated	O
infusion	O
with	O
regard	O
to	O
30-day	O
mortality	O

There	O
was	O
also	O
a	O
slightly	O
higher	O
rate	O
of	O
intracranial	D
hemorrhage	D
with	O
the	O
double-bolus	T
method	T

Therefore	O
,	O
accelerated	T
infusion	T
of	T
alteplase	T
over	O
a	O
period	O
of	O
90	O
minutes	O
remains	O
the	O
preferred	O
regimen	O

BACKGROUND	O
:	O
Fenfluramine	T
and	O
phentermine	T
have	O
been	O
individually	O
approved	O
as	O
anorectic	T
agents	T
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O

When	O
used	O
in	O
combination	O
the	O
drugs	O
may	O
be	O
just	O
as	O
effective	O
as	O
either	O
drug	O
alone	O
,	O
with	O
the	O
added	O
advantages	O
of	O
the	O
need	O
for	O
lower	O
doses	O
of	O
each	O
agent	O
and	O
perhaps	O
fewer	O
side	O
effects	O

Although	O
the	O
combination	O
has	O
not	O
been	O
approved	O
by	O
the	O
FDA	O
,	O
in	O
1996	O
the	O
total	O
number	O
of	O
prescriptions	O
in	O
the	O
United	O
States	O
for	O
fenfluramine	T
and	O
phentermine	T
exceeded	O
18	O
million	O

<	O
TO_SEE	O
>	O
METHODS	O
:	O
We	O
identified	O
valvular	O
heart	O
diseasein	O
24	O
women	O
treated	O
with	O
fenfluramine-phentermine	O
who	O
had	O
no	O
history	O
of	O
cardiac	O
disease	O

The	O
women	O
presented	O
with	O
cardiovascular	D
symptoms	D
or	O
a	O
heart	D
murmur	D

As	O
increasing	O
numbers	O
of	O
these	O
patients	O
with	O
similar	O
clinical	O
features	O
were	O
identified	O
,	O
there	O
appeared	O
to	O
be	O
an	O
association	O
between	O
these	O
features	O
and	O
fenfluramine-phentermine	T
therapy	T

RESULTS	O
:	O
Twenty-four	O
women	O
(	O
mean	O
(	O
+/-SD	O
)	O
age	O
,	O
44+/-8	O
years	O
)	O
were	O
evaluated	O
12.3+/-7.1	O
months	O
after	O
the	O
initiation	O
of	O
fenfluramine-phentermine	T
therapy	T

Echocardiography	O
demonstrated	O
unusual	O
valvular	O
morphology	O
and	O
regurgitation	O
in	O
all	O
patients	O

Both	O
right-sided	O
and	O
left-sided	O
heart	O
valves	O
were	O
involved	O

Eight	O
women	O
also	O
had	O
newly	O
documented	O
pulmonary	D
hypertension	D

To	O
date	O
,	O
cardiac	T
surgical	T
intervention	T
has	O
been	O
required	O
in	O
five	O
patients	O

The	O
heart	O
valves	O
had	O
a	O
glistening	O
white	O
appearance	O

Histopathological	O
findings	O
included	O
plaque-like	O
encasement	O
of	O
the	O
leaflets	O
and	O
chordal	O
structures	O
with	O
intact	O
valve	O
architecture	O

The	O
histopathological	O
features	O
were	O
identical	O
to	O
those	O
seen	O
in	O
carcinoid	O
or	O
ergotamine-induced	O
valve	D
disease	D

CONCLUSIONS	O
:	O
These	O
cases	O
arouse	O
concern	O
that	O
fenfluramine-phentermine	T
therapy	T
may	O
be	O
associated	O
with	O
valvular	D
heart	D
disease	D

Candidates	O
for	O
fenfluramine-phentermine	T
therapy	T
should	O
be	O
informed	O
about	O
serious	O
potential	O
adverse	O
effects	O
,	O
including	O
pulmonary	D
hypertension	D
and	O
valvular	D
heart	D
disease	D

<	O
TO_SEE	O
>	O
Between	O
1987	O
and	O
1992	O
,	O
all	O
patients	O
presenting	O
to	O
the	O
senior	O
author	O
with	O
a	O
symptomatic	O
failed	O
silicone	O
implant	O
arthroplasty	O
refractory	O
to	O
conservative	O
treatment	O
were	O
converted	O
to	O
a	O
metatarsophalangeal	O
joint	O
arthrodesis	O

Internal	O
fixation	O
was	O
achieved	O
with	O
either	O
dual	O
intrameduilary	O
threaded	O
Steinmann	O
pins	O
or	O
an	O
obliquely	O
placed	O
AO	O
compression	O
screw	O
and	O
a	O
three-	O
or	O
four-hole	O
one-third	O
tubular	O
dorsal	O
neutralization	O
plate	O

Bone	T
grafting	T
was	O
used	O
to	O
maintain	O
hallux	O
length	O

Successful	O
arthrodesis	T
was	O
achieved	O
in	O
all	O
five	O
feet	O
in	O
patients	O
with	O
rheumatoid	D
arthritis	D

Subjectively	O
,	O
patients	O
improved	O
from	O
an	O
average	O
of	O
0.69	O
before	O
arthrodesis	T
to	O
4.89	O
after	O
arthrodesis	T

The	O
average	O
walking	O
tolerance	O
improved	O
from	O
1.11	O
to	O
4.80	O
,	O
and	O
the	O
overall	O
level	O
of	O
satisfaction	O
improved	O
from	O
0.0	O
to	O
4.79	O

The	O
patient	O
's	O
ability	O
to	O
wear	O
shoes	O
improved	O
from	O
0.87	O
to	O
3.1	O

Successful	O
arthrodesis	T
produces	O
a	O
foot	O
that	O
is	O
more	O
functional	O
and	O
durable	O
than	O
excisional	T
arthroplasty	T

Subjectively	O
,	O
these	O
patients	O
stated	O
that	O
their	O
level	O
of	O
pain	O
,	O
walking	O
tolerance	O
,	O
and	O
overall	O
satisfaction	O
improved	O
significantly	O
after	O
the	O
arthrodesis	T

Clinically	O
,	O
there	O
was	O
no	O
evidence	O
of	O
transfer	D
lesions	D
,	O
tenderness	O
,	O
or	O
hallux	D
subluxation	D

Hallux	O
length	O
was	O
well	O
maintained	O
after	O
surgery	T
with	O
bone	T
grafting	T
,	O
but	O
it	O
was	O
more	O
difficult	O
to	O
obtain	O
the	O
alignment	O
goals	O

The	O
average	O
postoperative	O
metatarsophalangeal	O
dorsiflexion	O
angle	O
was	O
15.6	O
degrees	O
and	O
the	O
first	O
metatarsophalangeal	O
angle	O
was	O
3.1	O
degrees	O

Despite	O
this	O
,	O
patient	O
satisfaction	O
was	O
high	O

Arthrodesis	T
of	O
the	O
first	O
metatarsophalangeal	O
joint	O
using	O
a	O
bone	T
graft	T
to	O
salvage	O
failed	O
silicone	T
implant	T
arthroplasty	T
produces	O
acceptable	O
subjective	O
and	O
radiographic	O
results	O

Although	O
technically	O
demanding	O
,	O
it	O
provides	O
long-term	O
stability	O
to	O
the	O
hallux	O
,	O
restores	O
weightbearing	O
,	O
and	O
allows	O
for	O
maintenance	O
of	O
a	O
propulsive	O
gait	O

We	O
recommend	O
this	O
procedure	O
instead	O
of	O
an	O
excisional	T
arthroplasty	T
to	O
maintain	O
high	O
level	O
of	O
function	O
and	O
overall	O
patient	O
satisfaction	O

OBJECTIVE	O
:	O
To	O
estimate	O
the	O
crude	O
incidence	O
rates	O
of	O
cerebrovascular	D
accidents	D
among	O
the	O
black	O
residents	O
of	O
Harare	O

DESIGN	O
:	O
Prospective	O
community-based	O
study	O

SETTING	O
:	O
Black	O
residents	O
of	O
Harare	O
,	O
Zimbabwe	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
and	O
seventy-three	O
'first-ever	O
'	O
strokes	D
prospectively	O
identified	O
over	O
a	O
12-month	O
period	O

MAIN	O
OUTCOME	O
STUDY	O
FACTORS	O
:	O
Cerebrovascular	D
accident	D
first-week	O
fatality	O
rate	O
;	O
age-	O
and	O
sex-related	O
incidence	O

RESULTS	O
:	O
The	O
crude	O
incidence	O
rate	O
was	O
estimated	O
to	O
be	O
30.7	O
per	O
100000	O
(	O
95	O
%	O
confidence	O
interval	O
27.1-34.4	O
)	O
and	O
the	O
standardised	O
rate	O
was	O
68	O
per	O
100000	O

Fifty-one	O
per	O
cent	O
of	O
stroke	D
victims	O
were	O
below	O
the	O
age	O
of	O
54	O
years	O

Thirty-five	O
per	O
cent	O
of	O
patients	O
died	O
within	O
1	O
week	O
of	O
the	O
stroke	O

Overall	O
,	O
the	O
age-specific	O
rates	O
for	O
both	O
sexes	O
rose	O
with	O
age	O
,	O
with	O
the	O
rates	O
for	O
women	O
being	O
higher	O
at	O
all	O
age	O
strata	O
except	O
for	O
the	O
group	O
45-54	O
years	O

CONCLUSION	O
:	O
With	O
a	O
standardised	O
rate	O
of	O
68	O
per	O
100000	O
and	O
a	O
first-week	O
mortality	O
rate	O
of	O
35	O
%	O
,	O
stroke	D
must	O
now	O
be	O
considered	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
the	O
population	O

OBJECTIVE	O
:	O
To	O
explore	O
the	O
long-term	O
effect	O
of	O
calcium	T
supplementation	T
during	O
pregnancy	O
on	O
the	O
offspring	O
's	O
blood	O
pressure	O
during	O
childhood	O

DESIGN	O
:	O
Follow	O
up	O
of	O
a	O
population	O
enrolled	O
in	O
a	O
double	O
blind	O
,	O
randomised	O
,	O
placebo	O
controlled	O
trial	O

SETTING	O
:	O
Perinatal	O
research	O
unit	O
,	O
World	O
Health	O
Organisation	O
's	O
collaborative	O
research	O
centre	O

SUBJECTS	O
:	O
591	O
children	O
at	O
a	O
mean	O
age	O
of	O
7	O
years	O
whose	O
mothers	O
were	O
randomly	O
assigned	O
during	O
pregnancy	O
to	O
receive	O
2	O
g/day	O
of	O
elemental	O
calcium	O
(	O
n	O
=	O
298	O
)	O
or	O
placebo	O
(	O
n	O
=	O
293	O
)	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Mean	O
blood	O
pressure	O
and	O
rate	O
of	O
high	D
blood	D
pressure	D
of	O
children	O

RESULTS	O
:	O
Overall	O
,	O
systolic	O
blood	O
pressure	O
was	O
lower	O
in	O
the	O
calcium	O
group	O
(	O
mean	O
difference	O
-1.4	O
mm	O
Hg	O
;	O
95	O
%	O
confidence	O
interval	O
-3.2	O
to	O
0.5	O
)	O
than	O
in	O
the	O
placebo	O
group	O

The	O
effect	O
was	O
found	O
predominantly	O
among	O
children	O
whose	O
body	O
mass	O
index	O
at	O
assessment	O
was	O
above	O
the	O
median	O
for	O
this	O
population	O
(	O
mean	O
difference	O
in	O
systolic	O
blood	O
pressure	O
-5.8	O
mm	O
Hg	O
(	O
-9.8	O
mm	O
Hg	O
to	O
-1.7	O
mm	O
Hg	O
)	O
for	O
children	O
with	O
an	O
index	O
>	O
17.5	O
and	O
-3.2	O
mm	O
Hg	O
(	O
-6.3	O
mm	O
Hg	O
to	O
-0.1	O
mm	O
Hg	O
)	O
for	O
those	O
with	O
an	O
index	O
of	O
>	O
15.7	O
to	O
17.5	O
)	O

The	O
risk	O
of	O
high	O
systolic	O
blood	O
pressure	O
was	O
also	O
lower	O
in	O
the	O
calcium	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
relative	O
risk	O
0.59	O
;	O
0.39	O
to	O
0.90	O
)	O
and	O
particularly	O
among	O
children	O
in	O
the	O
highest	O
fourth	O
of	O
body	O
mass	O
index	O
(	O
0.43	O
;	O
0.26	O
to	O
0.71	O
)	O

CONCLUSION	O
:	O
Calcium	T
supplementation	T
during	O
pregnancy	O
is	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
in	O
the	O
offspring	O
,	O
particularly	O
among	O
overweight	O
children	O

The	O
fast	O
reaction	O
of	O
peroxynitrite	O
with	O
CO2	O
and	O
the	O
high	O
concentration	O
of	O
dissolved	O
CO2	O
in	O
vivo	O
(	O
ca	O

1	O
mM	O
)	O
suggest	O
that	O
CO2	O
modulates	O
most	O
of	O
the	O
reactions	O
of	O
peroxynitrite	O
in	O
biological	O
systems	O

The	O
addition	O
of	O
peroxynitrite	O
to	O
CO2	O
produces	O
of	O
the	O
adduct	O
ONOO-CO2-	O
(	O
1	O
)	O

The	O
production	O
of	O
1	O
greatly	O
accelerates	O
the	O
decomposition	O
of	O
peroxynitrite	O
to	O
give	O
nitrate	O

We	O
now	O
show	O
that	O
the	O
formation	O
of	O
1	O
is	O
followed	O
by	O
reformation	O
of	O
CO2	O
(	O
rather	O
than	O
another	O
carbonate	O
species	O
such	O
as	O
CO3	O
=	O
or	O
HCO3-	O
)	O

To	O
show	O
this	O
,	O
it	O
is	O
necessary	O
to	O
study	O
systems	O
with	O
limiting	O
concentrations	O
of	O
CO2	O

(	O
When	O
CO2	O
is	O
present	O
in	O
excess	O
,	O
its	O
concentration	O
remains	O
nearly	O
constant	O
during	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
the	O
recycling	O
of	O
CO2	O
,	O
although	O
it	O
occurs	O
,	O
can	O
not	O
be	O
detected	O
kinetically	O
)	O

We	O
find	O
that	O
CO2	O
is	O
a	O
true	O
catalyst	O
of	O
the	O
decomposition	O
of	O
peroxynitrite	O
,	O
and	O
this	O
fundamental	O
insight	O
into	O
its	O
action	O
must	O
be	O
rationalized	O
by	O
any	O
in	O
vivo	O
or	O
in	O
vitro	O
reaction	O
mechanism	O
that	O
is	O
proposed	O

When	O
the	O
concentration	O
of	O
CO2	O
is	O
lower	O
than	O
that	O
of	O
peroxynitrite	O
,	O
the	O
reformation	O
of	O
CO2	O
amplifies	O
the	O
fraction	O
of	O
peroxynitrite	O
that	O
reacts	O
with	O
CO2	O

Even	O
low	O
concentrations	O
of	O
CO2	O
that	O
result	O
from	O
the	O
dissolution	O
of	O
ambient	O
CO2	O
can	O
have	O
pronounced	O
catalytic	O
effects	O

These	O
effects	O
can	O
cause	O
deviations	O
from	O
predicted	O
kinetic	O
behavior	O
in	O
studies	O
of	O
peroxynitrite	O
in	O
noncarbonate	O
buffers	O
in	O
vitro	O
,	O
and	O
since	O
1	O
and	O
other	O
intermediates	O
derived	O
from	O
it	O
are	O
oxidants	O
and/or	O
nitrating	O
agents	O
,	O
some	O
of	O
the	O
reactions	O
attributed	O
to	O
peroxynitrite	O
may	O
depend	O
on	O
the	O
availability	O
of	O
CO2	O

A	O
prospective	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
6-month	O
study	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
ropinirole	T
,	T
a	T
nonergoline	T
D2-dopamine	T
agonist	T
,	O
in	O
patients	O
with	O
early	D
Parkinson	D
's	D
disease	D
(	O
n	O
=	O
241	O
;	O
Hoehn	O
&	O
#	O
38	O
;	O
Yahr	O
stages	O
I	O
to	O
III	O
)	O
with	O
limited	O
or	O
no	O
prior	O
dopaminergic	T
therapy	T

Patients	O
(	O
mean	O
age	O
,	O
62.8	O
years	O
)	O
,	O
stratified	O
by	O
concomitant	O
use	O
of	O
selegiline	T
,	O
were	O
randomized	O
to	O
ropinirole	T
(	O
n	O
=	O
116	O
)	O
or	O
placebo	O
(	O
n	O
=	O
125	O
)	O

The	O
starting	O
dose	O
of	O
ropinirole	T
was	O
0.25	O
mg	O
tid	O
with	O
titration	O
to	O
at	O
least	O
1.5	O
mg	O
tid	O
(	O
maximum	O
dose	O
,	O
8	O
mg	O
tid	O
)	O

Primary	O
efficacy	O
endpoint	O
was	O
the	O
percentage	O
improvement	O
in	O
Unified	O
Parkinson	D
's	D
Disease	D
Rating	O
Scale	O
(	O
UPDRS	O
)	O
motor	O
score	O

Ropinirole-treated	O
patients	O
had	O
a	O
significantly	O
greater	O
percentage	O
improvement	O
in	O
UPDRS	O
motor	O
score	O
than	O
patients	O
who	O
received	O
placebo	O
(	O
+24	O
%	O
vs	O
-3	O
%	O
;	O
p	O
&	O
#	O
60	O
;	O
0.001	O
)	O

Ropinirole	T
was	O
well	O
tolerated	O
and	O
patient	O
withdrawals	O
were	O
infrequent	O

Most	O
adverse	O
experiences	O
were	O
related	O
to	O
peripheral	O
dopaminergic	O
activity	O

Ropinirole	T
monotherapy	T
is	O
an	O
effective	O
and	O
well-tolerated	O
therapeutic	O
option	O
for	O
treatment	O
of	O
early	D
Parkinson	D
's	D
disease	D

Starfish	O
oocytes	O
can	O
be	O
fertilized	O
after	O
germinal	O
vesicle	O
breakdown	O
(	O
GVBD	O
)	O
and	O
artificial	O
parthenogenesis	O
can	O
be	O
induced	O
by	O
activating	O
the	O
oocytes	O
after	O
GVBD	O
(	O
post-GVBD	O
activation	O
)	O

In	O
the	O
present	O
study	O
,	O
parthenogenotes	O
were	O
obtained	O
by	O
the	O
activation	O
of	O
immature	O
oocytes	O
with	O
caffeine	O
before	O
treatment	O
with	O
1-methyladenine	T
(	T
1-MeAde	T
)	T
to	O
induce	O
oocyte	O
maturation	O

Most	O
of	O
the	O
caffeine-treated	O
eggs	O
developed	O
as	O
tetraploids	O
,	O
as	O
parthenogenotes	O
produced	O
by	O
the	O
post-GVBD	O
activation	O

The	O
parthengenotes	O
were	O
derived	O
only	O
from	O
eggs	O
that	O
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
mostly	O
from	O
eggs	O
failing	O
to	O
extrude	O
a	O
second	O
polar	O
body	O

Eggs	O
derived	O
from	O
immature	O
oocytes	O
activated	O
by	O
A23187	O
,	O
treated	O
with	O
1-MeAde	T
and	O
post-treated	O
with	O
cytochalasin	T
B	T
failed	O
to	O
extrude	O
polar	O
bodies	O
,	O
and	O
eventually	O
developed	O
into	O
parthenogenetic	O
embryos	O

These	O
results	O
indicate	O
that	O
the	O
present	O
parthenogenesis	O
mechanism	O
shares	O
the	O
same	O
characteristics	O
as	O
that	O
achieved	O
by	O
post-GVBD	O
activation	O
in	O
the	O
suppression	O
of	O
polar	O
body	O
formation	O
as	O
a	O
key	O
means	O
for	O
successful	O
starfish	O
parthenogenesis	O

We	O
hypothesized	O
that	O
fluoride	T
partly	O
acts	O
by	O
changing	O
the	O
levels	O
of	O
circulating	O
calcium-regulating	O
hormones	O
and	O
skeletal	O
growth	O
factors	O

The	O
effects	O
of	O
oral	T
fluoride	T
on	O
24	O
female	O
,	O
Dutch-Belted	O
,	O
young	O
adult	O
rabbits	O
were	O
studied	O

The	O
rabbits	O
were	O
divided	O
into	O
two	O
study	O
groups	O
,	O
one	O
control	O
and	O
the	O
other	O
receiving	O
about	O
16	O
mg	O
fluoride/rabbit/day	O
in	O
their	O
drinking	O
water	O

After	O
6	O
months	O
of	O
fluoride	T
dosing	T
,	O
all	O
rabbits	O
were	O
euthanized	O
and	O
bone	O
and	O
blood	O
samples	O
were	O
taken	O
for	O
analyses	O

Fluoride	T
treatment	T
increased	O
serum	O
and	O
bone	O
fluoride	O
levels	O
by	O
over	O
an	O
order	O
of	O
magnitude	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
but	O
did	O
not	O
affect	O
body	O
weight	O
or	O
the	O
following	O
serum	O
biochemical	O
variables	O
:	O
urea	O
,	O
creatinine	O
,	O
phosphorus	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
bilirubin	O
,	O
SGOT	O
,	O
or	O
total	O
alkaline	O
phosphatase	O

<	O
TO_SEE	O
>	O
No	O
skeletal	D
fluorosis	D
or	O
osteomalacia	D
was	O
observed	O
histologically	O
,	O
nor	O
did	O
fluoride	T
affect	O
serum	O
PTH	O
or	O
Vitamin	O
D	O
metabolites	O
(	O
P	O
>	O
0.4	O
)	O

BAP	O
was	O
increased	O
37	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
by	O
fluoride	O
;	O
serum	O
TRAP	O
was	O
increased	O
42	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
;	O
serum	O
IGF-1	O
was	O
increased	O
40	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O

Fluoride	T
increased	O
the	O
vertebral	O
BV/TV	O
by	O
35	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
and	O
tibial	O
ash	O
weight	O
by	O
10	O
%	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O

However	O
,	O
the	O
increases	O
in	O
bone	O
mass	O
and	O
bone	O
formation	O
were	O
not	O
reflected	O
in	O
improved	O
bone	O
strength	O

Fluoride	O
decreased	O
bone	O
strength	O
by	O
about	O
19	O
%	O
in	O
the	O
L5	O
vertebra	O
(	O
P	O
&	O
#	O
60	O
;	O
0.01	O
)	O
and	O
25	O
%	O
in	O
the	O
femoral	O
neck	O
(	O
P	O
&	O
#	O
60	O
;	O
0	O

05	O
)	O

X-ray	O
diffraction	O
showed	O
altered	O
mineral	O
crystal	O
thickness	O
in	O
fluoride-treated	O
bones	O
(	O
P	O
&	O
#	O
60	O
;	O
0.001	O
)	O
,	O
and	O
there	O
was	O
a	O
negative	O
association	O
between	O
crystal	O
width	O
and	O
fracture	O
stress	O
of	O
the	O
femur	O
(	O
P	O
&	O
#	O
60	O
;	O
0.02	O
)	O

In	O
conclusion	O
,	O
fluoride	O
's	O
effects	O
on	O
bone	O
mass	O
and	O
bone	O
turnover	O
were	O
not	O
mediated	O
by	O
PTH	O

IGF-1	O
was	O
increased	O
by	O
fluoride	O
and	O
was	O
associated	O
with	O
increased	O
bone	O
turnover	O
,	O
but	O
was	O
not	O
correlated	O
with	O
bone	O
formation	O
markers	O

High-dose	O
fluoride	T
treatment	T
did	O
not	O
improve	O
,	O
but	O
decreased	O
,	O
bone	O
strength	O
in	O
rabbits	O
,	O
even	O
in	O
the	O
absence	O
of	O
impaired	O
mineralization	O

PURPOSE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
various	O
methods	O
of	O
managing	O
the	O
posterior	O
capsule	O
and	O
anterior	O
vitreous	O
on	O
the	O
rate	O
of	O
posterior	D
capsule	D
opacification	D
in	O
pediatric	O
eyes	O
implanted	O
with	O
posterior	T
chamber	T
intraocular	T
lenses	T
(	T
PC	T
IOLs	T
)	T

SETTING	O
:	O
Cullen	O
Eye	O
Institute	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
,	O
USA	O

METHODS	O
:	O
We	O
reviewed	O
the	O
charts	O
of	O
20	O
eyes	O
of	O
15	O
children	O
(	O
aged	O
1.5	O
to	O
2	O
years	O
)	O
who	O
had	O
primary	O
cataract	D
surgery	T
with	T
PC	T
IOL	T
implantation	T
during	O
the	O
past	O
5	O
years	O

The	O
posterior	O
capsule	O
and	O
anterior	O
vitreous	O
were	O
managed	O
in	O
a	O
variety	O
of	O
ways	O
:	O
In	O
5	O
eyes	O
,	O
the	O
posterior	O
capsule	O
was	O
left	O
intact	O
;	O
in	O
15	O
eyes	O
,	O
a	O
posterior	T
continuous	T
curvilinear	T
capsulorhexis	T
(	T
PCCC	T
)	T
was	O
performed	O
-	O
6	O
with	O
and	O
9	O
without	O
anterior	T
vitrectomy	T
;	O
in	O
8	O
eyes	O
,	O
posterior	T
optic	T
capture	T
was	O
performed	O
-	O
3	O
with	O
and	O
5	O
without	O
vitrectomy	T

The	O
follow-up	O
ranged	O
from	O
1	O
to	O
4.5	O
years	O
(	O
mean	O
2	O
years	O
)	O

RESULTS	O
:	O
Visually	O
significant	O
secondary	O
cataract	D
developed	O
in	O
the	O
five	O
eyes	O
with	O
intact	O
posterior	O
capsules	O
and	O
in	O
the	O
four	O
eyes	O
that	O
had	O
PCCC	T
without	O
vitrectomy	T
and	O
without	O
posterior	T
optic	T
capture	T
(	O
i.e	O
.	O
,	O
the	O
optic	O
was	O
left	O
in	O
the	O
capsular	O
bag	O
)	O

The	O
optical	O
axis	O
remained	O
clear	O
in	O
the	O
six	O
eyes	O
that	O
had	O
PC	T
IOL	T
implantation	T
with	O
vitrectomy	T
(	O
with	O
or	O
without	O
posterior	T
optic	T
capture	T
)	O

Initially	O
,	O
all	O
eyes	O
that	O
had	O
optic	T
capture	T
without	O
vitrectomy	T
also	O
remained	O
clear	O
,	O
but	O
after	O
6	O
months	O
,	O
four	O
of	O
five	O
developed	O
opacification	D

CONCLUSION	O
:	O
In	O
this	O
series	O
,	O
PCCC	T
with	T
anterior	T
vitrectomy	T
was	O
the	O
only	O
effective	O
method	O
of	O
preventing	O
or	O
delaying	O
secondary	D
cataract	D
formation	D
in	O
infants	O
and	O
children	O

Evidence	O
for	O
the	O
presence	O
of	O
a	O
serotonin1A	O
(	O
5-HT1A	O
)	O
receptor	O
subtype	O
in	O
the	O
salmonid	O
fish	O
brain	O
has	O
recently	O
been	O
presented	O

In	O
the	O
present	O
study	O
the	O
potent	O
5-HT1A	O
receptor	O
agonist	O
,	O
8-hydroxy-2-	O
(	O
di-n-propylamino	O
)	O
-tetralin	O
(	O
8-OH-DPAT	O
)	O
was	O
tested	O
for	O
its	O
effect	O
on	O
plasma	O
cortisol	O
concentrations	O
in	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O

Blood	O
was	O
sampled	O
and	O
8-OH-DPAT	O
administered	O
through	O
a	O
catheter	O
in	O
the	O
dorsal	O
aorta	O

Thirty	O
minutes	O
after	O
the	O
injection	O
of	O
40	O
microg	O
of	O
8-OH-DPAT/kg	O
,	O
plasma	O
cortisol	O
levels	O
had	O
increased	O
from	O
12	O
to	O
149	O
ng/ml	O
,	O
whereupon	O
they	O
fell	O
,	O
reaching	O
baseline	O
levels	O
after	O
4	O
h.	O
The	O
effect	O
of	O
1-40	O
microg	O
8-OH-DPAT/kg	O
on	O
plasma	O
cortisol	O
concentrations	O
was	O
dose-dependent	O

The	O
results	O
lends	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
brain	O
serotonergic	O
system	O
plays	O
a	O
key	O
role	O
in	O
integrating	O
autonomic	O
,	O
behavioral	O
and	O
neuroendocrine	O
stress-responses	O
in	O
fish	O
as	O
well	O
as	O
mammals	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
structural	O
and	O
biochemical	O
organization	O
,	O
but	O
also	O
the	O
function	O
of	O
the	O
serotonergic	O
system	O
has	O
been	O
conserved	O
during	O
vertebrate	O
evolution	O

OBJECTIVE	O
:	O
To	O
assess	O
the	O
medicalising	O
effect	O
of	O
prescribing	O
antibiotics	T
for	O
sore	D
throat	D

SETTING	O
:	O
11	O
general	O
practices	O
in	O
England	O

DESIGN	O
:	O
Randomised	O
trial	O
of	O
three	O
approaches	O
to	O
sore	D
throat	D
:	O
a	O
10	O
day	O
prescription	O
of	O
antibiotics	T
,	O
no	O
antibiotics	O
,	O
or	O
a	O
delayed	O
prescription	O
if	O
the	O
sore	D
throat	D
had	O
not	O
started	O
to	O
settle	O
after	O
three	O
days	O

PATIENTS	O
:	O
716	O
patients	O
aged	O
4	O
and	O
over	O
with	O
sore	D
throat	D
and	O
an	O
abnormal	O
physical	O
sign	O
:	O
84	O
%	O
had	O
tonsillitis	D
or	O
pharyngitis	D

OUTCOME	O
MEASURES	O
:	O
Number	O
and	O
rate	O
of	O
patients	O
making	O
a	O
first	O
return	O
with	O
sore	D
throat	D
,	O
pharyngitis	D
,	O
or	O
tonsillitis	D

Early	O
returns	O
(	O
within	O
two	O
weeks	O
)	O
and	O
complications	O
(	O
otitis	D
media	D
,	O
sinusitis	D
,	O
quinsy	D
)	O

Outcomes	O
were	O
documented	O
in	O
675	O
subjects	O
(	O
94	O
%	O
)	O

RESULTS	O
:	O
Mean	O
follow	O
up	O
time	O
was	O
similar	O
(	O
antibiotic	O
group	O
1.07	O
years	O
,	O
other	O
two	O
groups	O
1.03	O
years	O
)	O

More	O
of	O
those	O
initially	O
prescribed	O
antibiotics	T
initially	O
returned	O
to	O
the	O
surgery	O
with	O
sore	D
throat	D
(	O
38	O
%	O
v	O
27	O
%	O
,	O
adjusted	O
hazard	O
ratio	O
for	O
return	O
1.39	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
1.03	O
to	O
1.89	O
)	O

Antibiotics	T
prescribed	O
for	O
sore	D
throat	D
during	O
the	O
previous	O
year	O
had	O
an	O
additional	O
effect	O
(	O
hazard	O
ratio	O
1.69	O
,	O
1.20	O
to	O
2.37	O
)	O

Longer	O
duration	O
of	O
illness	O
(	O
>	O
5	O
days	O
)	O
was	O
associated	O
with	O
increased	O
return	O
within	O
six	O
weeks	O
(	O
hazard	O
ratio	O
2.90	O
,	O
1.70	O
to	O
4.92	O
)	O

Prior	O
attendance	O
with	O
upper	D
respiratory	D
conditions	D
was	O
also	O
associated	O
with	O
increased	O
reattendance	O

There	O
was	O
no	O
difference	O
between	O
groups	O
in	O
early	O
return	O
(	O
13/238	O
(	O
5.5	O
%	O
)	O
v	O
27/437	O
(	O
6	O
%	O
)	O
)	O
,	O
or	O
complications	O
(	O
2/236	O
(	O
0.8	O
%	O
)	O
v	O
3/434	O
(	O
0.7	O
%	O
)	O
)	O

CONCLUSIONS	O
:	O
Complications	O
and	O
early	O
return	O
resulting	O
from	O
no	O
or	O
delayed	O
prescribing	O
of	O
antibiotics	T
for	O
sore	D
throat	D
are	O
rare	O

Both	O
current	O
and	O
previous	O
prescribing	O
for	O
sore	D
throat	D
increase	O
reattendance	O

To	O
avoid	O
medicalising	O
a	O
self	O
limiting	O
illness	O
doctors	O
should	O
avoid	O
antibiotics	T
or	O
offer	O
a	O
delayed	O
prescription	O
for	O
most	O
patients	O
with	O
sore	D
throat	D

This	O
study	O
was	O
designed	O
to	O
determine	O
and	O
compare	O
the	O
dose-response	O
characteristics	O
,	O
speed	O
of	O
onset	O
,	O
and	O
relative	O
potency	O
of	O
single-dose	O
epidural	T
fentanyl	T
(	T
F	T
)	T
and	O
sufentanil	T
(	T
S	T
)	T
for	O
postoperative	D
pain	D
relief	D

<	O
TO_SEE	O
>	O
Eighty	O
women	O
undergoing	O
cesarean	O
section	O
(	O
C/S	O
)	O
with	O
epidural	O
2	O
%	O
lidocaine	O
with	O
epinephrine	O
(	O
1	O
:	O
200	O
,	O
000	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
double-blind	O
epidural	O
administration	O
of	O
F	O
(	O
25	O
,	O
50	O
,	O
100	O
,	O
or	O
200	O
microg	O
)	O
or	O
S	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
30	O
microg	O
)	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
upon	O
complaint	O
of	O
pain	O
postoperatively	O

Visual	O
analog	O
scales	O
(	O
VAS	O
,	O
0-100	O
mm	O
)	O
were	O
used	O
to	O
assess	O
pain	O
and	O
sedation	O
at	O
baseline	O
;	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
30	O
,	O
45	O
,	O
and	O
60	O
min	O
;	O
and	O
every	O
30	O
min	O
until	O
further	O
analgesia	O
was	O
requested	O

The	O
study	O
was	O
terminated	O
at	O
30	O
min	O
if	O
satisfactory	O
analgesia	O
was	O
not	O
achieved	O

Side	O
effects	O
were	O
recorded	O

A	O
dose-response	O
was	O
demonstrated	O
for	O
both	O
opioids	O

F	O
25	O
microg	O
and	O
S	O
5	O
microg	O
were	O
ineffective	O
,	O
with	O
significantly	O
fewer	O
women	O
achieving	O
VAS	O
scores	O
&	O
#	O
60	O
;	O
10	O
mm	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
compared	O
with	O
F	O
100	O
or	O
200	O
microg	O
and	O
S	O
20	O
or	O
30	O
microg	O
)	O

F	O
100	O
and	O
200	O
microg	O
and	O
S	O
20	O
and	O
30	O
microg	O
all	O
achieved	O
VAS	O
scores	O
&	O
#	O
60	O
;	O
10	O
mm	O
in	O
all	O
women	O
with	O
no	O
differences	O
in	O
time	O
to	O
50	O
%	O
reduction	O
in	O
VAS	O
(	O
mean	O
11-16	O
min	O
)	O
and	O
no	O
differences	O
in	O
duration	O
of	O
analgesia	O
(	O
mean	O
117-138	O
min	O
)	O

The	O
50	O
%	O
and	O
95	O
%	O
effective	O
dose	O
values	O
for	O
each	O
opioid	O
to	O
achieve	O
a	O
VAS	O
score	O
&	O
#	O
60	O
;	O
10	O
mm	O
were	O
F	O
33	O
microg	O
and	O
92	O
microg	O
and	O
S	O
6.7	O
microg	O
and	O
17.5	O
microg	O

There	O
were	O
no	O
differences	O
among	O
groups	O
in	O
sedation	O
scores	O
or	O
side	O
effects	O

Our	O
data	O
suggest	O
that	O
the	O
relative	O
analgesic	O
potency	O
of	O
epidural	O
S	O
:	O
F	O
is	O
approximately	O
5	O
and	O
that	O
there	O
are	O
no	O
differences	O
between	O
the	O
opioids	O
in	O
the	O
onset	O
,	O
duration	O
,	O
and	O
effectiveness	O
of	O
analgesia	O
when	O
equianalgesic	O
doses	O
are	O
administered	O
postoperatively	O
after	O
lidocaine	O
anesthesia	O
for	O
C/S	O

We	O
describe	O
2	O
cases	O
in	O
which	O
intraoperative	O
transesophageal	O
echocardiography	O
detected	O
complications	O
related	O
to	O
the	O
proximal	O
coronary	O
arteries	O
during	O
homograft	T
aortic	T
valve	T
and	T
root	T
replacement	T

In	O
both	O
cases	O
,	O
cardiopulmonary	T
bypass	T
could	O
not	O
be	O
discontinued	O
despite	O
the	O
use	O
of	O
large	O
doses	O
of	O
inotropic	T
drugs	T

Transesophageal	O
echocardiography	O
demonstrated	O
aliasing	O
on	O
color	O
flow	O
mapping	O
in	O
the	O
left	O
main	O
coronary	O
artery	O
in	O
1	O
case	O
and	O
proximal	O
right	O
coronary	O
artery	O
in	O
the	O
other	O
,	O
along	O
with	O
severely	O
depressed	O
left	O
ventricular	O
anterior	O
wall	O
and	O
right	O
ventricular	O
function	O
,	O
respectively	O

Coronary	T
artery	T
bypass	T
grafting	T
was	O
performed	O
in	O
both	O
cases	O
,	O
and	O
the	O
outcome	O
was	O
successful	O

<	O
TO_SEE	O
>	O
Granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
has	O
been	O
used	O
to	O
improve	O
granulocyte	O
count	O
in	O
chronic	O
neutropenia	O
and	O
myelodysplasia	O
,	O
to	O
minimize	O
the	O
incidence	O
and	O
duration	O
of	O
neutropenia	O
during	O
conventional	O
chemotherapy	O
,	O
and	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
prior	O
to	O
leukapheresis	O
for	O
use	O
in	O
autologous	O
and	O
allogeneic	O
marrow	O
transplantation	O

The	O
most	O
common	O
toxicity	O
is	O
bone	D
pain	D
,	O
and	O
other	O
reactions	O
such	O
as	O
inflammation	D
at	O
the	O
site	O
of	O
injection	T
have	O
also	O
occurred	O

In	O
patients	O
with	O
chronic	D
neutropenia	D
,	O
splenomegaly	D
has	O
been	O
described	O
with	O
long-term	O
use	O
,	O
and	O
extramedullary	D
hematopoiesis	D
has	O
also	O
been	O
reported	O

However	O
,	O
thus	O
far	O
,	O
no	O
life-threatening	O
sequelae	O
of	O
these	O
effects	O
are	O
found	O
in	O
the	O
literature	O

We	O
now	O
describe	O
a	O
case	O
of	O
spontaneous	O
splenic	D
rupture	D
four	O
days	O
following	O
a	O
six-day	O
course	O
of	O
G-CSF	T
therapy	T
in	O
an	O
allogeneic	O
donor	O
of	O
peripheral	O
blood	O
stem	O
cells	O

Evidence-based	O
medicine	O
(	O
EBM	O
)	O
aids	O
clinical	O
decision	O
making	O
in	O
all	O
fields	O
of	O
medicine	O
,	O
including	O
primary	O
care	O

General	O
practice	O
is	O
characterized	O
by	O
particular	O
emphasis	O
on	O
the	O
doctor-patient	O
relationship	O
and	O
on	O
biomedical	O
,	O
personal	O
and	O
contextual	O
perspectives	O
in	O
diagnosis	O

Most	O
evidence	O
available	O
to	O
general	O
practitioners	O
(	O
GPs	O
)	O
addresses	O
only	O
the	O
bio-medical	O
perspective	O
and	O
is	O
often	O
not	O
directly	O
applicable	O
to	O
primary	O
care	O
,	O
as	O
it	O
derives	O
from	O
secondary	O
or	O
tertiary	O
care	O

Emphasis	O
on	O
the	O
biomedical	O
domain	O
and	O
the	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
alone	O
reflects	O
a	O
reductionist	O
approach	O
that	O
fails	O
to	O
do	O
justice	O
to	O
the	O
philosophy	O
of	O
general	O
practice	O

The	O
art	O
of	O
medicine	O
is	O
founded	O
on	O
context	O
,	O
anecdote	O
,	O
patient	O
stories	O
of	O
illness	O
and	O
personal	O
experience	O
,	O
and	O
we	O
should	O
continue	O
to	O
blend	O
this	O
with	O
good	O
quality	O
and	O
appropriate	O
research	O
findings	O
in	O
patient	O
care	O

Abdominal	D
tuberculosis	D
is	O
not	O
uncommon	O
in	O
the	O
UK	O
,	O
especially	O
in	O
Asian	O
immigrants	O

It	O
resembles	O
Crohn	D
's	D
disease	D
clinically	O
and	O
radiologically	O
,	O
and	O
it	O
may	O
be	O
difficult	O
to	O
differentiate	O
between	O
them	O
,	O
even	O
at	O
laparotomy	O
or	O
histology	O

The	O
distinction	O
is	O
important	O
,	O
however	O
,	O
for	O
proper	O
management	O
of	O
the	O
two	O
conditions	O

<	O
TO_SEE	O
>	O
Every	O
effort	O
must	O
be	O
made	O
to	O
exclude	O
abdominal	D
tuberculosis	D
before	O
the	O
patient	O
is	O
diagnosed	O
as	O
having	O
Crohn	D
's	D
disease	D
and	O
is	O
treated	O
with	O
steroids	T

PURPOSE	O
:	O
The	O
American	O
Urological	O
Association	O
convened	O
the	O
Female	D
Stress	D
Urinary	D
Incontinence	D
Clinical	O
Guidelines	O
Panel	O
to	O
analyze	O
the	O
literature	O
regarding	O
surgical	T
procedures	T
for	O
treating	O
stress	D
urinary	D
incontinence	D
in	O
the	O
otherwise	O
healthy	O
female	O
subject	O
and	O
to	O
make	O
practice	O
recommendations	O
based	O
on	O
the	O
treatment	O
outcomes	O
data	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
panel	O
searched	O
the	O
MEDLINE	O
data	O
base	O
for	O
all	O
articles	O
through	O
1993	O
on	O
surgical	T
treatment	T
of	O
female	D
stress	D
urinary	D
incontinence	D

Outcomes	O
data	O
were	O
extracted	O
from	O
articles	O
accepted	O
after	O
panel	O
review	O

The	O
data	O
were	O
then	O
meta-analyzed	O
to	O
produce	O
outcome	O
estimates	O
for	O
alternative	O
surgical	T
procedures	T

RESULTS	O
:	O
The	O
data	O
indicate	O
that	O
after	O
48	O
months	O
retropubic	T
suspensions	T
and	O
slings	T
appear	O
to	O
be	O
more	O
efficacious	O
than	O
transvaginal	T
suspensions	T
,	O
and	O
also	O
more	O
efficacious	O
than	O
anterior	T
repairs	T

The	O
literature	O
suggests	O
higher	O
complication	O
rates	O
when	O
synthetic	O
materials	O
are	O
used	O
for	O
slings	T

CONCLUSIONS	O
:	O
The	O
panel	O
found	O
sufficient	O
acceptable	O
long-term	O
outcomes	O
data	O
(	O
longer	O
than	O
48	O
months	O
)	O
to	O
conclude	O
that	O
surgical	T
treatment	T
of	O
female	D
stress	D
urinary	D
incontinence	D
is	O
effective	O
,	O
offering	O
a	O
long-term	O
cure	O
in	O
a	O
significant	O
percentage	O
of	O
women	O

The	O
evidence	O
supports	O
surgery	T
as	O
initial	O
therapy	O
and	O
as	O
a	O
secondary	O
form	O
of	O
therapy	O
after	O
failure	O
of	O
other	O
treatments	O
for	O
stress	D
urinary	D
incontinence	D

Retropubic	T
suspensions	T
and	O
slings	T
are	O
the	O
most	O
efficacious	O
procedures	O
for	O
long-term	O
success	O
(	O
based	O
on	O
cure/dry	O
rates	O
)	O

However	O
,	O
in	O
the	O
panel	O
's	O
opinion	O
retropubic	T
suspensions	T
and	O
sling	T
procedures	T
are	O
associated	O
with	O
slightly	O
higher	O
complication	O
rates	O
,	O
including	O
longer	O
convalescence	O
and	O
postoperative	D
voiding	D
dysfunction	D

A	O
55-year-old	O
lady	O
underwent	O
repeat	O
aortic	T
valve	T
replacement	T
using	O
a	O
16-mm	O
Carbomedics	O
prosthesis	O

She	O
made	O
an	O
uneventful	O
postoperative	O
recovery	O
and	O
now	O
leads	O
an	O
unrestricted	O
life	O

Doppler	O
echocardiography	O
reveals	O
a	O
21-mm	O
Hg	O
gradient	O
across	O
the	O
valve	O
at	O
rest	O

This	O
did	O
not	O
increase	O
with	O
an	O
infusion	O
of	O
30	O
mcg/kg	O
per	O
min	O
of	O
dobutamine	O
,	O
which	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
cardiac	O
output	O
from	O
1.96	O
to	O
5.46	O
l/min	O

BACKGROUND	O
:	O
For	O
more	O
than	O
30	O
years	O
it	O
has	O
been	O
known	O
that	O
gastric	O
acid	O
secretion	O
is	O
inversely	O
related	O
to	O
the	O
extent	O
and	O
severity	O
of	O
corpal	D
gastritis	D

We	O
therefore	O
evaluated	O
the	O
effect	O
of	O
cure	O
of	O
Helicobacter	D
pylori	D
infection	D
on	O
basal	O
and	O
pentagastrin-stimulated	O
acid	O
secretion	O

METHODS	O
:	O
Basal	O
acid	O
output	O
(	O
BAO	O
)	O
and	O
maximal	O
acid	O
output	O
(	O
MAO	O
)	O
were	O
assessed	O
in	O
11	O
H.	O
pylori-infected	O
dyspeptic	O
patients	O
(	O
8	O
women	O
and	O
3	O
men	O
;	O
mean	O
age	O
,	O
28	O
years	O
)	O
before	O
and	O
after	O
successful	O
anti-H	O

pylori	O
therapy	O

RESULTS	O
:	O
The	O
gastritis	O
index	O
was	O
significantly	O
lower	O
after	O
therapy	O
and	O
was	O
associated	O
with	O
an	O
increase	O
in	O
both	O
BAO	O
and	O
MAO	O
after	O
cure	O
of	O
the	O
H.	D
pylori	D
infection	D
(	O
BAO	O
from	O
0.3	O
mmol/h	O
and	O
MAO	O
from	O
4.8	O
mmol/h	O
to	O
19	O
mmol/	O
h	O
)	O

Basal	O
and	O
stimulated	O
acid	O
concentrations	O
also	O
increased	O
(	O
29.1	O
+/-	O
36.6	O
to	O
54	O
+/-	O
31	O
mmol/l	O
and	O
72.5	O
+/-	O
46	O
to	O
120.1	O
+/-	O
30	O
mmol/l	O
,	O
respectively	O
,	O
for	O
basal	O
and	O
stimulated	O
acid	O
concentrations	O
;	O
P	O
&	O
#	O
60	O
;	O
0.05	O
for	O
peak	O
and	O
MAO	O
,	O
P	O
=	O
0.07	O
for	O
BAO	O
)	O

CONCLUSION	O
:	O
Gastric	O
acid	O
secretion	O
increased	O
into	O
the	O
normal	O
range	O
after	O
successful	O
treatment	O
of	O
H.	D
pylori	D
infection	D
,	O
suggesting	O
that	O
gastric	O
function	O
can	O
recover	O
to	O
normal	O
or	O
almost	O
normal	O
after	O
cure	O
of	O
H.	D
pylori	D
infection	D

OBJECTIVE	O
:	O
Reports	O
suggest	O
that	O
there	O
is	O
an	O
increased	O
incidence	O
of	O
preeclampsia	D
after	O
a	O
previously	O
normal	O
pregnancy	O
if	O
there	O
is	O
a	O
change	O
in	O
paternity	O

We	O
hypothesize	O
that	O
there	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	D
(	D
proteinuric	D
hypertension	D
)	D
in	O
women	O
conceiving	O
by	O
intrauterine	O
insemination	O
with	O
donor	O
sperm	O
versus	O
intrauterine	O
insemination	O
with	O
partner	O
sperm	O

STUDY	O
DESIGN	O
:	O
This	O
was	O
a	O
retrospective	O
cohort	O
study	O

In	O
women	O
with	O
primary	O
infertility	D
all	O
pregnancies	O
achieved	O
by	O
either	O
partner	O
or	O
donor	O
intrauterine	T
insemination	T
carried	O
to	O
birth	O
of	O
a	O
fetus	O
(	O
>	O
20	O
weeks	O
)	O
were	O
identified	O

The	O
medical	O
records	O
were	O
examined	O
for	O
the	O
maternal	O
and	O
pregnancy	O
outcome	O
data	O

The	O
relative	O
risk	O
and	O
95	O
%	O
confidence	O
interval	O
were	O
calculated	O
for	O
the	O
risk	O
of	O
preeclampsia	D

The	O
baseline	O
data	O
were	O
compared	O
with	O
t	O
tests	O
,	O
chi	O
2	O
analysis	O
and	O
Fisher	O
's	O
exact	O
test	O
where	O
appropriate	O

RESULTS	O
:	O
Forty-four	O
patients	O
in	O
the	O
partner	O
intrauterine	T
insemination	T
group	O
and	O
37	O
in	O
the	O
donor	T
insemination	T
group	O
were	O
identified	O
as	O
having	O
primary	O
infertility	D

Three	O
cases	O
of	O
mild	O
preeclampsia	D
were	O
found	O
in	O
the	O
partner	T
insemination	T
program	O
and	O
nine	O
cases	O
of	O
preeclampsia	D
(	O
five	O
severe	O
,	O
four	O
mild	O
)	O
in	O
the	O
donor	T
insemination	T
program	O
(	O
relative	O
risk	O
1.85	O
,	O
95	O
%	O
confidence	O
interval	O
1.20	O
to	O
2.85	O
)	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	D
in	O
women	O
conceiving	O
by	O
intrauterine	T
insemination	T
with	O
washed	O
donor	O
sperm	O
compared	O
with	O
intrauterine	T
insemination	T
with	O
washed	O
partner	O
sperm	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
a	O
higher	O
incidence	O
of	O
preeclampsia	D
in	O
women	O
conceiving	O
by	O
intrauterine	T
insemination	T
with	O
washed	O
donor	O
sperm	O
compared	O
with	O
intrauterine	T
insemination	T
with	O
washed	O
partner	O
sperm	O
.	O

This	O
supports	O
,	O
indirectly	O
,	O
an	O
immunologic	O
basis	O
for	O
preeclampsia	D

The	O
antigenic	O
factor	O
would	O
appear	O
to	O
be	O
located	O
on	O
the	O
sperm	O
as	O
opposed	O
to	O
the	O
seminal	O
fluid	O
itself	O

After	O
a	O
rapid	O
examination	O
of	O
a	O
few	O
basic	O
concepts	O
concerning	O
cellular	O
aging	O
and	O
programmed	O
cell	O
death	O
,	O
the	O
aging	O
of	O
the	O
tissues	O
and	O
organs	O
,	O
the	O
authors	O
discuss	O
the	O
principal	O
theories	O
on	O
senescence	O

They	O
underline	O
that	O
it	O
is	O
necessary	O
to	O
agree	O
in	O
considering	O
the	O
various	O
genetic	O
and	O
epigenetic	O
,	O
endogenous	O
and	O
exogenous	O
mechanisms	O
that	O
lead	O
to	O
the	O
complex	O
aging	O
phenomenon	O
multiple	O
and	O
interrelated	O

In	O
particular	O
they	O
stress	O
the	O
hypothesis	O
that	O
senescence	O
can	O
be	O
due	O
to	O
a	O
sum	O
of	O
molecular	O
damages	O
caused	O
by	O
free	O
radicals	O
,	O
and	O
to	O
the	O
loss	O
of	O
telomeric	O
DNA	O

Radical	O
reactions	O
can	O
cause	O
mutations	O
,	O
inactivation	O
or	O
a	O
decrease	O
in	O
the	O
turnover	O
of	O
mitochondrial	O
DNA	O
which	O
is	O
more	O
vulnerable	O
than	O
the	O
nuclear	O
genoma	O
to	O
the	O
attack	O
of	O
mutagenic	O
agents	O
,	O
acting	O
also	O
as	O
a	O
continuous	O
source	O
of	O
initial	O
and/or	O
promoting	O
factors	O
of	O
the	O
carcinogenetic	O
process	O

The	O
somatic	O
cells	O
become	O
senescent	O
because	O
during	O
cell	O
division	O
,	O
they	O
lose	O
the	O
mechanisms	O
for	O
the	O
lengthening	O
of	O
the	O
telomere	O

The	O
telomerase	O
prevents	O
the	O
shortening	O
of	O
telomeres	O
in	O
neoplastic	O
cells	O
and	O
therefore	O
renders	O
them	O
immortal	O

Paradoxically	O
the	O
protection	O
of	O
the	O
telomere	O
is	O
exactly	O
what	O
must	O
be	O
avoided	O
in	O
the	O
case	O
of	O
tumor	O
cells	O

Recently	O
the	O
demonstration	O
that	O
telomerase	O
is	O
not	O
always	O
involved	O
in	O
the	O
restoration	O
of	O
telomere	O
length	O
shows	O
the	O
complexity	O
of	O
the	O
problems	O
connected	O
to	O
the	O
cause	O
of	O
senescence	O

Chromosomally	O
integrated	O
retroviral	O
switch	O
(	O
S	O
)	O
substrates	O
have	O
been	O
developed	O
to	O
reveal	O
switch	O
recombinase-like	O
activities	O
(	O
SRLA	O
)	O
in	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O

Switch	O
substrate	O
retrovectors	O
(	O
SSR	O
)	O
contain	O
a	O
long-terminal	O
repeat-driven	O
neomycin	O
(	O
Neo	O
)	O
gene	O
for	O
proviral	O
chromosomal	O
maintenance	O
(	O
pre-	O
and	O
post-S	O
recombination	O
)	O
and	O
a	O
CMV	O
promoter-driven	O
,	O
chimeric	O
hygromycin-thymidine	O
kinase	O
(	O
Hytk	O
)	O
gene	O
(	O
flanked	O
by	O
S	O
mu	O
and	O
S	O
gamma	O
2b	O
recombination	O
targets	O
)	O
to	O
select	O
for	O
(	O
ganciclovir	O
)	O
and	O
against	O
(	O
hygromycin	O
B	O
)	O
S	O
region	O
recombination	O

The	O
retro-substrates	O
'	O
strong	O
,	O
constitutive	O
promoters	O
ensure	O
that	O
variations	O
in	O
cellular	O
switch	O
recombinase	O
activities	O
are	O
independent	O
of	O
S	O
region	O
accessibility	O
control	O

By	O
initially	O
selecting	O
for	O
proviral	O
integrants	O
in	O
hygromycin	O
followed	O
by	O
shifting	O
into	O
neomycin	O
+	O
ganciclovir	O
to	O
select	O
for	O
S	O
sequence-mediated	O
deletions	O
,	O
switch	O
recombinations	O
can	O
be	O
specifically	O
forestalled	O
in	O
B	O
cell	O
lines	O
whilst	O
most	O
switch-incompetent	O
cells	O
do	O
not	O
survive	O
secondary	O
selection	O

A	O
qualitative	O
,	O
direct	O
PCR	O
assay	O
reveals	O
that	O
SSR	O
recombinations	O
are	O
stochastic	O
in	O
B	O
cell	O
lines	O
generating	O
a	O
product	O
array	O
akin	O
to	O
natural	O
GH	O
class	O
switching	O

A	O
semi-quantitative	O
DC-PCR	O
assay	O
detects	O
a	O
significant	O
recombinase	O
activity	O
only	O
in	O
a	O
restricted	O
set	O
of	O
late	O
stage	O
pre-B	O
and	O
mature	O
B	O
cell	O
lines	O

BCL1B1	O
mature	O
B	O
cells	O
have	O
the	O
highest	O
level	O
of	O
recombinase	O
activity	O
with	O
25	O
%	O
or	O
more	O
of	O
proviral	O
integrants	O
accumulating	O
S	O
mu/S	O
gamma	O
2b	O
substrate	O
recombinations	O
within	O
10-14	O
cell	O
generations	O

The	O
SSR	O
recombinase	O
assay	O
can	O
be	O
performed	O
in	O
a	O
transient	O
fashion	O
wherein	O
extensive	O
,	O
B	O
cell-specific	O
recombination	O
can	O
be	O
visualized	O
within	O
only	O
a	O
few	O
cell	O
divisions	O
post	O
proviral	O
integration	O

We	O
propose	O
that	O
switch	O
recombinase	O
activity	O
becomes	O
activated	O
during	O
B	O
cell	O
ontogeny	O
independent	O
of	O
or	O
prior	O
to	O
the	O
acquisition	O
of	O
CH	O
locus	O
accessibility	O
and	O
that	O
endogenous	O
S	O
segment	O
targeting	O
to	O
pre-existing	O
recombinase	O
requires	O
a	O
level	O
of	O
accessibility	O
beyond	O
transcriptional	O
activation	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
prevalence	O
of	O
illicit	O
drug	O
abuse	O
and	O
alcohol	O
use	O
in	O
an	O
obstetric	O
population	O
based	O
in	O
an	O
urban	O
maternity	O
hospital	O

SETTING	O
:	O
A	O
collaborative	O
study	O
between	O
the	O
Rotunda	O
Hospital	O
,	O
Dublin	O
and	O
the	O
Irish	O
National	O
Drug	O
Advisory	O
&	O
#	O
38	O
;	O
Treatment	O
Centre	O

DESIGN	O
:	O
A	O
prospective	O
study	O
consisting	O
of	O
anonymous	O
,	O
unlinked	O
urine	O
testing	O
of	O
504	O
'first	O
visit	O
'	O
antenatal	O
patients	O
and	O
a	O
separate	O
group	O
of	O
515	O
patients	O
six	O
weeks	O
after	O
delivery	O

METHODS	O
&	O
#	O
38	O
;	O
OUTCOME	O
MEASURES	O
:	O
Toxicological	O
screening	O
using	O
enzyme-linked	O
immunoassay	O
techniques	O
,	O
with	O
all	O
positive	O
samples	O
being	O
reanalysed	O

Drug	O
histories	O
were	O
taken	O
and	O
samples	O
were	O
tested	O
for	O
alcohol	O
and	O
six	O
of	O
the	O
most	O
commonly	O
abused	O
drugs	O

The	O
pre-	O
and	O
postnatal	O
prevalence	O
of	O
abuse	O
was	O
matched	O
with	O
demographic	O
data	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
chemical	O
substance	O
misuse	O
in	O
the	O
antenatal	O
population	O
was	O
2.8	O
%	O
and	O
5.6	O
%	O
in	O
the	O
postnatal	O
population	O

Substances	O
identified	O
included	O
benzodiazepines	O
,	O
cannabis	O
,	O
amphetamines	O
,	O
opiates	O
and	O
cocaine	O

Less	O
than	O
2	O
%	O
of	O
samples	O
tested	O
positive	O
for	O
alcohol	O

None	O
of	O
the	O
women	O
yielding	O
positive	O
samples	O
had	O
been	O
pre-identified	O
on	O
the	O
basis	O
of	O
history	O

A	O
significant	O
proportion	O
of	O
the	O
women	O
were	O
in	O
the	O
high	O
risk	O
categories	O
with	O
regard	O
to	O
age	O
and	O
socio-economic	O
status	O

CONCLUSION	O
:	O
The	O
prevalence	O
of	O
drug	O
misuse	O
antenatally	O
was	O
nearly	O
3	O
%	O
and	O
postnatally	O
almost	O
6	O
%	O

Substance	O
abusers	O
in	O
pregnancy	O
are	O
more	O
likely	O
to	O
be	O
single	O
,	O
unemployed	O
,	O
and	O
to	O
have	O
had	O
a	O
previous	O
pregnancy	O

Schizophrenic	D
illnesses	D
occur	O
with	O
approximately	O
the	O
same	O
incidence	O
in	O
all	O
human	O
populations	O
with	O
a	O
characteristic	O
distribution	O
(	O
slightly	O
earlier	O
in	O
males	O
)	O
of	O
ages	O
of	O
onset	O

Given	O
that	O
the	O
predisposition	O
(	O
which	O
presumably	O
is	O
genetic	O
)	O
is	O
associated	O
with	O
a	O
procreative	O
disadvantage	O
why	O
do	O
such	O
illnesses	O
persist	O
?	O
Here	O
it	O
is	O
suggested	O
that	O
these	O
conditions	O
are	O
a	O
manifestation	O
of	O
genetic	O
diversity	O
in	O
the	O
evolution	O
of	O
the	O
specifically	O
human	O
characteristic	O
of	O
language	O
,	O
an	O
innovation	O
that	O
has	O
occurred	O
by	O
a	O
process	O
of	O
progressive	O
hemispheric	O
specialization-the	O
establishment	O
of	O
dominance	O
for	O
some	O
critical	O
component	O
of	O
language	O
in	O
one	O
or	O
the	O
other	O
hemisphere	O

Individuals	O
who	O
develop	O
schizophrenic	D
symptoms	D
show	O
lesser	O
anatomical	O
and	O
functional	O
asymmetries	O
than	O
the	O
population	O
as	O
a	O
whole	O
;	O
such	O
symptoms	O
may	O
reflect	O
'dominance	O
failure	O
'	O
for	O
language	O

Cloacal	D
anomalies	D
are	O
extremely	O
rare	O
and	O
have	O
variable	O
presentations	O

Prenatal	O
diagnosis	O
can	O
be	O
difficult	O
especially	O
if	O
they	O
present	O
in	O
late	O
gestation	O

Here	O
we	O
present	O
two	O
cases	O
diagnosed	O
in	O
the	O
late	O
third	O
trimester	O
and	O
review	O
the	O
literature	O
regarding	O
prenatal	O
diagnosis	O
of	O
cloacal	D
anomalies	D

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
patients	O
with	O
myocardial	D
amyloidosis	D
due	O
either	O
to	O
AL	O
(	O
primary	O
)	O
amyloid	O
or	O
familial	O
amyloid	O
have	O
distinguishing	O
echocardiographic	O
or	O
electrocardiographic	O
features	O
;	O
and	O
to	O
compare	O
the	O
prevalence	O
of	O
heart	D
failure	D
and	O
survival	O
in	O
the	O
two	O
types	O
of	O
amyloidosis	D
in	O
relation	O
to	O
echocardiographic	O
findings	O

DESIGN	O
:	O
Blinded	O
group	O
comparison	O
of	O
randomly	O
selected	O
cases	O
of	O
cardiac	D
amyloidosis	D

SETTING	O
:	O
International	O
referral	O
centre	O
for	O
amyloid	O
research	O
and	O
treatment	O

PATIENTS	O
:	O
36	O
patients	O
with	O
cardiac	D
amyloid	D
heart	D
disease	D
,	O
of	O
whom	O
12	O
had	O
familial	O
and	O
24	O
had	O
primary	O
AL	O
amyloidosis	D

RESULTS	O
:	O
Familial	O
and	O
AL	O
echocardiograms	O
were	O
morphologically	O
indistinguishable	O
,	O
with	O
similar	O
left	O
ventricular	O
wall	O
thickness	O
,	O
mean	O
(	O
SD	O
)	O
15.4	O
(	O
2.3	O
)	O
nu	O
15.8	O
(	O
2.5	O
)	O
mm	O
,	O
respectively	O
;	O
right	O
ventricular	O
wall	O
thickness	O
was	O
also	O
similar	O
between	O
amyloid	O
types	O
:	O
9.6	O
(	O
2.8	O
)	O
nu	O
9.7	O
(	O
6.5	O
)	O
mm	O
,	O
respectively	O

Doppler	O
indices	O
of	O
left	O
and	O
right	O
ventricular	O
function	O
,	O
left	O
ventricular	O
volume	O
,	O
and	O
ejection	O
fraction	O
were	O
also	O
similar	O

Low	O
voltage	O
electrocardiograms	O
(	O
&	O
#	O
60	O
;	O
0.5	O
mV	O
)	O
were	O
more	O
common	O
in	O
the	O
AL	O
(	O
16/24	O
,	O
67	O
%	O
)	O
than	O
in	O
the	O
familial	O
group	O
(	O
4/12	O
,	O
25	O
%	O
)	O
,	O
P	O
&	O
#	O
60	O
;	O
0.05	O

The	O
one	O
year	O
survival	O
for	O
familial	O
and	O
AL	O
forms	O
was	O
92	O
%	O
(	O
11/12	O
)	O
nu	O
38	O
%	O
(	O
6/24	O
)	O
,	O
respectively	O
,	O
with	O
virtually	O
all	O
deaths	O
due	O
to	O
cardiac	O
causes	O

CONCLUSIONS	O
:	O
Although	O
cardiac	O
involvement	O
is	O
echocardiographically	O
indistinguishable	O
,	O
cardiac	O
mortality	O
is	O
very	O
different	O
between	O
the	O
two	O
forms	O
of	O
amyloidosis	D

Preservation	O
of	O
electrocardiographic	O
voltage	O
in	O
familial	O
amyloidosis	D
suggests	O
that	O
the	O
particular	O
biochemical	O
characteristics	O
of	O
distinct	O
types	O
of	O
amyloid	O
fibril	O
have	O
different	O
pathological	O
effects	O
on	O
the	O
myocardium	O

This	O
distinction	O
becomes	O
critical	O
in	O
the	O
evaluation	O
,	O
treatment	O
,	O
and	O
management	O
of	O
patients	O
who	O
have	O
a	O
diagnosis	O
within	O
the	O
spectrum	O
of	O
the	O
protein	D
deposition	D
diseases	D

OBJECTIVE	O
:	O
To	O
examine	O
the	O
relationship	O
between	O
plasma	O
plasminogen	O
activator	O
inhibitor	O
1	O
(	O
PAI-1	O
)	O
activity	O
and	O
PAI-1	O
gene	O
(	O
4G/5G	O
)	O
polymorphism	O
and	O
diabetic	D
retinopathy	D
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	D

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
We	O
studied	O
171	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	D
between	O
the	O
ages	O
of	O
30-70	O
years	O
in	O
a	O
population-based	O
epidemiological	O
survey	O

Plasma	O
PAI-1	O
activity	O
was	O
measured	O
by	O
a	O
spectrophotometric	O
assay	O
and	O
PAI-1	O
4G/5G	O
promoter	O
genotype	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
allele-specific	O
primers	O

Retinopathy	D
was	O
assessed	O
by	O
ophthalmoscopy	O
after	O
pupillary	O
dilation	O
and	O
classified	O
as	O
any	O
retinopathy	D
or	O
as	O
nonproliferative	O
and	O
proliferative	O

RESULTS	O
:	O
Retinopathy	D
was	O
present	O
in	O
70	O
(	O
41	O
%	O
)	O
subjects	O
,	O
and	O
4	O
(	O
2.3	O
%	O
)	O
subjects	O
had	O
proliferative	O
retinopathy	D

Plasma	O
PAI-1	O
activity	O
was	O
not	O
significantly	O
different	O
among	O
subjects	O
with	O
and	O
without	O
retinopathy	D
(	O
17.1	O
+/-	O
vs.	O
19.7	O
+/-	O
9.1	O
arbitrary	O
units	O
(	O
AU	O
)	O
/ml	O
,	O
P	O
=	O
0.09	O
)	O

PAI-1	O
activity	O
was	O
negatively	O
correlated	O
with	O
duration	O
of	O
diabetes	D
(	O
rs	O
=	O
-0.18	O
,	O
P	O
=	O
0.02	O
)	O

In	O
a	O
logistic	O
regression	O
analysis	O
controlled	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
and	O
duration	O
of	O
diabetes	D
,	O
any	O
retinopathy	D
was	O
significantly	O
associated	O
with	O
fasting	O
plasma	O
glucose	O
concentrations	O
(	O
P	O
&	O
#	O
60	O
;	O
0.05	O
)	O
,	O
2-h	O
postload	O
glucose	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
HbA1c	O
(	O
P	O
=	O
0.008	O
)	O
,	O
but	O
not	O
with	O
PAI-1	O
activity	O
(	O
P	O
=	O
0.48	O
)	O

The	O
prevalence	O
of	O
retinopathy	D
in	O
the	O
three	O
genotype	O
groups	O
differed	O
significantly	O
(	O
4G/4G	O
,	O
4G/5G	O
,	O
and	O
5G/5G	O
were	O
44	O
,	O
49	O
,	O
and	O
24	O
%	O
,	O
respectively	O
;	O
chi	O
2	O
=	O
8.22	O
,	O
df	O
=	O
2	O
,	O
P	O
=	O
0.016	O
)	O
and	O
remained	O
significant	O
after	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
BMI	O
,	O
duration	O
of	O
diabetes	D
,	O
glycated	O
hemoglobin	O
,	O
and	O
urine	O
albumin-to-creatine	O
ratio	O
in	O
a	O
logistic	O
regression	O
analysis	O

The	O
odds	O
ratios	O
for	O
retinopathy	D
in	O
subjects	O
with	O
4G/4G	O
and	O
4G/5G	O
,	O
compared	O
with	O
the	O
5G/5G	O
genotype	O
,	O
were	O
2.0	O
and	O
3.1	O
,	O
respectively	O

CONCLUSIONS	O
:	O
Although	O
diabetic	D
retinopathy	D
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	D
is	O
not	O
associated	O
with	O
PAI-1	O
activity	O
,	O
subjects	O
with	O
the	O
4G/4G	O
and	O
4G/5G	O
genotype	O
had	O
a	O
higher	O
prevalence	O
of	O
retinopathy	D
compared	O
with	O
5G/5G	O
PAI-1genotype	O

These	O
preliminary	O
findings	O
indicate	O
that	O
in	O
Pima	O
Indians	O
with	O
type	O
2	O
diabetes	D
,	O
presence	O
of	O
the	O
4G	O
allele	O
of	O
the	O
PAI-1	O
gene	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
diabetic	D
retinopathy	D

BACKGROUND	O
:	O
Diagnostic	O
peritoneal	O
lavage	O
(	O
DPL	O
)	O
is	O
used	O
to	O
diagnose	O
intra-abdominal	D
injury	D
in	O
patients	O
with	O
stab	D
wounds	D
and	O
blunt	D
trauma	D

Because	O
exploratory	T
celiotomy	T
is	O
routinely	O
performed	O
on	O
patients	O
with	O
gunshot	D
wounds	D
to	D
the	D
abdomen	D
,	O
DPL	O
is	O
rarely	O
employed	O

However	O
,	O
several	O
studies	O
have	O
questioned	O
routine	O
exploration	O
and	O
have	O
drawn	O
attention	O
to	O
the	O
associated	O
morbidity	O
of	O
negative	O
celiotomy	O

Diagnostic	O
peritoneal	O
lavage	O
is	O
an	O
easily	O
performed	O
and	O
inexpensive	O
test	O
that	O
may	O
be	O
useful	O
in	O
this	O
situation	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
performance	O
of	O
DPL	O
in	O
the	O
diagnosis	O
of	O
intra-abdominal	D
injury	D
in	O
hemodynamically	O
stable	O
patients	O
with	O
gunshot	D
wounds	D
to	O
the	O
abdomen	O

DESIGN	O
:	O
A	O
prospective	O
clinical	O
trial	O

SETTING	O
:	O
Two	O
urban	O
trauma	O
centers	O

PATIENTS	O
:	O
Patients	O
with	O
gunshot	D
wounds	D
to	O
the	O
abdomen	O
and	O
a	O
systolic	O
blood	O
pressure	O
of	O
at	O
least	O
90	O
mm	O
Hg	O
